<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cells</journal-id><journal-id journal-id-type="iso-abbrev">Cells</journal-id><journal-id journal-id-type="publisher-id">cells</journal-id><journal-title-group><journal-title>Cells</journal-title></journal-title-group><issn pub-type="epub">2073-4409</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6830311</article-id><article-id pub-id-type="doi">10.3390/cells8101123</article-id><article-id pub-id-type="publisher-id">cells-08-01123</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Estrogen-Receptor Expression and Function in Female Reproductive Disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Tang</surname><given-names>Zi-Run</given-names></name><xref ref-type="aff" rid="af1-cells-08-01123">1</xref><xref ref-type="author-notes" rid="fn1-cells-08-01123">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Rui</given-names></name><xref ref-type="aff" rid="af1-cells-08-01123">1</xref><xref ref-type="author-notes" rid="fn1-cells-08-01123">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Lian</surname><given-names>Zheng-Xing</given-names></name><xref ref-type="aff" rid="af1-cells-08-01123">1</xref><xref rid="c1-cells-08-01123" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1187-3037</contrib-id><name><surname>Deng</surname><given-names>Shou-Long</given-names></name><xref ref-type="aff" rid="af2-cells-08-01123">2</xref><xref rid="c1-cells-08-01123" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Yu</surname><given-names>Kun</given-names></name><xref ref-type="aff" rid="af1-cells-08-01123">1</xref><xref rid="c1-cells-08-01123" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-cells-08-01123"><label>1</label>Beijing Key Laboratory for Animal Genetic Improvement, National Engineering Laboratory for Animal Breeding, Key Laboratory of Animal Genetics and Breeding of the Ministry of Agriculture, College of Animal Science and Technology, China Agricultural University, Beijing 100193, China; <email>S20183040519@cau.edu.cn</email> (Z.-R.T.); <email>zr123@cau.edu.cn</email> (R.Z.)</aff><aff id="af2-cells-08-01123"><label>2</label>CAS Key Laboratory of Genome Sciences and Information, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing 100101, China</aff><author-notes><corresp id="c1-cells-08-01123"><label>*</label>Correspondence: <email>lianzhx@cau.edu.cn</email> (Z.-X.L.), <email>popo84350746@163.com</email> (S.-L.D.); <email>young137@163.com</email> (K.Y.); Tel.: +86-(010)-6273-3904 (Z.-X.L.); +86-(010)-8409-7698 (S.-L.D.); +86-(010)-6273-2681 (K.Y.)</corresp><fn id="fn1-cells-08-01123"><label>&#x02020;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>21</day><month>9</month><year>2019</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2019</year></pub-date><volume>8</volume><issue>10</issue><elocation-id>1123</elocation-id><history><date date-type="received"><day>29</day><month>8</month><year>2019</year></date><date date-type="accepted"><day>20</day><month>9</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2019 by the authors.</copyright-statement><copyright-year>2019</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Estrogen receptors (ER) include ER alpha, ER beta and new membrane receptor G protein-coupled receptor 30 (GPR30). Estrogen receptors are key receptors to maintain ovarian granulosa cell differentiation, follicle and oocyte growth and development, and ovulation function. The abnormal functions of estrogen, its receptors, and estradiol synthesis-related enzymes are closely related to clinical reproductive endocrine diseases, such as polycystic ovary syndrome (PCOS) and endometriosis (EMS). At present, hormone therapy is the main treatment for ovarian-related diseases, and a stable hormone environment is established by regulating ovarian function. In recent years, some estrogen-related drugs have made great progress, such as clomiphene, which is a nonsteroidal antiestrogen drug in clinical application. This article elaborates on the regulatory role of estrogen and its nuclear receptors and membrane receptors in oocyte development, especially female reproductive diseases related to the abnormal expression of estrogen and its receptors. We also highlighted the latest advances of treatment strategy for these diseases and the application of related targeted small molecule drugs in clinical research and treatment, so as to provide reference for the treatment of female reproductive diseases.</p></abstract><kwd-group><kwd>estrogen receptor</kwd><kwd>ovary</kwd><kwd>female reproductive disease</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-cells-08-01123"><title>1. Introduction</title><p>Estrogen mediates various effects throughout the body in both women and men, regulating physiological and pathological processes in the reproductive, cardiovascular, skeletal, endocrine, nervous, and immune systems. Therefore, it is also involved with scores of diseases, for example, infertility, endometriosis, polycystic ovary syndrome, and various cancers. The role that estrogen plays in the female reproductive system and the development of secondary sexual characteristics are primarily recognized as its most significant function. The cellular receptors of estrogen are crucial mediators of estrogen functions, which includes the nuclear receptor family (estrogen receptors (ER) alpha and ER beta) and membrane estrogen receptors (mERs; G protein-coupled receptor 30 (GPR30)). The physiology of estrogen and its receptors is especially complicated, as the history of estrogen-signaling mechanisms and systems originates more than 500 million years ago [<xref rid="B1-cells-08-01123" ref-type="bibr">1</xref>]. Interestingly, it was believed that the actions of estrogen were activated via a single receptor discovered in 1962 [<xref rid="B2-cells-08-01123" ref-type="bibr">2</xref>] until another estrogen receptor with high homology was identified in 1996 [<xref rid="B3-cells-08-01123" ref-type="bibr">3</xref>]. Since then, the former was renamed as ER&#x003b1; and the latter ER&#x003b2;. The third estrogen receptor was discovered and characterized in the 2000s [<xref rid="B4-cells-08-01123" ref-type="bibr">4</xref>,<xref rid="B5-cells-08-01123" ref-type="bibr">5</xref>], and was named the G protein-coupled receptor 30 (GPR30)/G protein-coupled estrogen receptor 1 (GPER).</p><p>Before the discovery of GPER, most physiological functions of estrogen receptors were widely recognized as ligand-activated transcription factors that belong to the nuclear hormone receptor family, including other steroid receptors such as progesterone, androgen, glucocorticoids, and mineralocorticoids [<xref rid="B6-cells-08-01123" ref-type="bibr">6</xref>]. However, this view was proved to be inaccurate by the time frame of transcriptional mechanisms because rapid cellular and physiological responses mediated by estrogen and other steroids had already been demonstrated. GPER identification allowed us to further understand the complicated activities and functions of estrogen and its receptors due to the rapid responses it classically mediates [<xref rid="B7-cells-08-01123" ref-type="bibr">7</xref>,<xref rid="B8-cells-08-01123" ref-type="bibr">8</xref>,<xref rid="B9-cells-08-01123" ref-type="bibr">9</xref>]. As described above, there are multiple and diverse cellular estrogen effects, including cAMP production, calcium mobilization inside cells, and the activation of various kinases, which include phosphoinositide 3-kinase (PI3K) and extracellular signal-regulated kinase (ERK). During these physiological processes, the expression and signaling mechanisms of estrogen receptors is complex and potentially exhibit redundant, independent, synergistic, and/or antagonistic actions [<xref rid="B10-cells-08-01123" ref-type="bibr">10</xref>]. As a result, the abnormal functions of estrogen receptors and estradiol synthesis-related enzymes are closely related to clinical diseases, especially in the reproductive and endocrine systems, such as polycystic ovary syndrome (PCOS) and endometriosis (EMS). Moreover, some numerous estrogenic compounds, including natural and synthetic ligands, are harmful to humans and other animals and were classified into endocrine-disrupting chemicals (EDCs) [<xref rid="B11-cells-08-01123" ref-type="bibr">11</xref>].</p><p>Owing to the critical role that estrogen receptors and estrogenic (including antiestrogenic) compounds play in various aspects of health and disease, numerous drugs have been synthesized by pharmaceutical companies, some of which have achieved great success as contraceptives, cancer treatment, and postmenopausal conditions including depression and osteoporosis. Part of these drugs are classified as selective estrogen receptor down-regulators or degraders (SERDs) because their binding to receptors leads to the proteasomal degradation of the receptor [<xref rid="B12-cells-08-01123" ref-type="bibr">12</xref>], while others are sorted into selective estrogen receptor modulators (SERMs) that play a role as agonists or antagonists of estrogen receptors in different types of estrogen-sensitive tissue [<xref rid="B13-cells-08-01123" ref-type="bibr">13</xref>].</p><p>As a matter of fact, because of the significant role that estrogen and its receptors play in multiple physiological and pathological processes, hormone therapy is the main treatment for ovarian-related diseases. For example, raloxifene can effectively reduce the incidence of breast and uterine cancer, tamoxifen is now used for the therapy of breast tumors in premenopausal and postmenopausal women, and diethylstilbestrol can be used to treat breast cancer patients. On the other hand, regulation of ovarian function can also maintain a stable hormone environment. In this review, we expound an overview of the regulatory role of estrogen, its receptors, and their cellular mechanisms in the female reproductive system, and recent advances in ovary diseases, followed by research and applications of the latest strategy of clinical therapy, so as to provide reference for the treatment of female ovarian diseases.</p></sec><sec id="sec2-cells-08-01123"><title>2. Estrogen Receptors</title><sec id="sec2dot1-cells-08-01123"><title>2.1. ER&#x003b1; and ER&#x003b2;</title><p>Estrogen receptors &#x003b1; and &#x003b2;, the critical mediators of the biological effects of estrogen, are encoded by genes <italic>ESR1</italic> and <italic>ESR2,</italic> located on nonhomologous chromosomes, respectively. Moreover, the expression of ER&#x003b1; and ER&#x003b2; differs greatly in tissue and cells. ER&#x003b1; is predominantly expressed in the uterus, ovaries, and breasts, while expressions of ER&#x003b2; are mainly found in the nervous system, ovaries, cardiovascular systems, and the male reproductive system [<xref rid="B14-cells-08-01123" ref-type="bibr">14</xref>]. The functions of ER&#x003b1; and ER&#x003b2; can be targeted by many therapeutic treatments of estrogen-related diseases. Those therapeutic interventions emphasize the significance of understanding the mechanisms of ER&#x003b1; and ER&#x003b2; to optimize treatment strategy.</p><p>Members of the nuclear-receptor superfamily of hormone receptors are constituted by four domains, ERs also included. These four structures and functioning domains are an NH<sub>2</sub> terminal domain, a COOH terminal ligand-binding domain, a hinge region, and a DNA-binding domain [<xref rid="B15-cells-08-01123" ref-type="bibr">15</xref>]. In addition, people found that ERs have a different domain with an unknown function: the carboxyl-terminal domain [<xref rid="B16-cells-08-01123" ref-type="bibr">16</xref>]. When we compared all of these five domains of ER&#x003b1; and ER&#x003b2;, we found that the NH2-terminal domains encompassed a ligand-independent activation function (AF1) domain that is capable of transcriptionally activating target genes with less than 20% similarity between the two forms. The amino acid identity of the DNA-binding domain in ER&#x003b1; and ER&#x003b2; is 97%, and this domain mainly acts as a mediator of the specific combination of ERs and DNA sequences [<xref rid="B17-cells-08-01123" ref-type="bibr">17</xref>]. On the contrary, the amino acid identity of the ligand-binding domains of ER&#x003b1; and ER&#x003b2; is 59%, with only minor structural differences between the two subtypes of ligand-binding pockets [<xref rid="B18-cells-08-01123" ref-type="bibr">18</xref>]. Moreover, the COOH terminal ligand-binding domain contains the transcription activation function 2 (AF2) domains, which are critical for the regulation of ligand-dependent transcription [<xref rid="B19-cells-08-01123" ref-type="bibr">19</xref>].</p><p>To mediate the effects of gene expression, nuclear hormone receptors are localized in the nucleus. As for estrogen receptors, inactivated ERs are mainly located in the nucleus (~95%), and the rest are located in the cytoplasm, and the membrane-localized ER&#x003b1; acts as an atypical G-protein coupled receptor [<xref rid="B20-cells-08-01123" ref-type="bibr">20</xref>,<xref rid="B21-cells-08-01123" ref-type="bibr">21</xref>]. Ligand activation usually leads to the dimerization of the monomer after dissociation from the chaperone (Hsp90), and translocate cytosolic receptors to the nucleus. Like other steroid hormone receptors, ERs act as homologous dimers and/or heterodimers in transcription, recruiting coregulators and combining them with estrogen response elements (EREs) [<xref rid="B6-cells-08-01123" ref-type="bibr">6</xref>,<xref rid="B22-cells-08-01123" ref-type="bibr">22</xref>,<xref rid="B23-cells-08-01123" ref-type="bibr">23</xref>]. Through combining with transcription factors, activated estrogen receptors can also indirectly bind to DNA, and transcription can be regulated by post-translational modification in the absence of a ligand [<xref rid="B24-cells-08-01123" ref-type="bibr">24</xref>]. A variety of ligands that are able to bind to the ER produce various conformations of the binding domain of the receptor-ligand (particularly helix 12), which produces numerous binding sites for coregulatory factors and other proteins. Furthermore, differential expression modes in different types of tissue lead to the complexity of ER and its ligands [<xref rid="B6-cells-08-01123" ref-type="bibr">6</xref>]. In summary, ERs regulate the expression of numerous genes, both positively and negatively, which depends on ligand and tissue [<xref rid="B25-cells-08-01123" ref-type="bibr">25</xref>].</p></sec><sec id="sec2dot2-cells-08-01123"><title>2.2. G Protein-Coupled Estrogen Receptor</title><p>GPER was originally identified in the laboratory as an orphan receptor (a cloned receptor with no known ligand) in the late 1990s and was named GPR30, which belongs to the 7-transmembrane G protein-coupled receptors family (GPCR) [<xref rid="B26-cells-08-01123" ref-type="bibr">26</xref>]. The vast majority of the available data illustrated that GPR30 specifically binds to estrogen and activates the intracellular signaling cascade normally associated with GPCR. That is the reason why GPR30 was designated as a GPER [<xref rid="B27-cells-08-01123" ref-type="bibr">27</xref>,<xref rid="B28-cells-08-01123" ref-type="bibr">28</xref>]. The transmembrane domains of the GPCR positions the amino terminus outside the cell, which is typically glycosylated; the carboxyl-terminal is in the cytoplasm and has great effects on receptor internalization through phosphorylation [<xref rid="B29-cells-08-01123" ref-type="bibr">29</xref>]. At present, the positioning of GPER is still controversial. Using both cell and tissue samples, most studies have resulted in consistent results with mainly the cytoplasmic membrane localization of GPER [<xref rid="B30-cells-08-01123" ref-type="bibr">30</xref>,<xref rid="B31-cells-08-01123" ref-type="bibr">31</xref>,<xref rid="B32-cells-08-01123" ref-type="bibr">32</xref>], while localization in the nucleus has been observed, too [<xref rid="B33-cells-08-01123" ref-type="bibr">33</xref>,<xref rid="B34-cells-08-01123" ref-type="bibr">34</xref>].</p><p>GPER is coupled with a heterotrimeric G protein that, in turn, regulates multiple downstream intracellular effectors. The most active natural form of estrogen is 17&#x003b2;-estradiol (E2), which is formed predominantly in the ovaries of premenopausal women. GPER was demonstrated to be involved in the rapid activation of ERK1/2 mediated by 17&#x003b2;-estradiol [<xref rid="B35-cells-08-01123" ref-type="bibr">35</xref>,<xref rid="B36-cells-08-01123" ref-type="bibr">36</xref>,<xref rid="B37-cells-08-01123" ref-type="bibr">37</xref>]. The downstream signaling pathway is involved in the activation of metalloproteinase mediated by Src, which releases heparin-binding EGF, followed by the transactivation of EGFR and then ERK1/2. After that, the capability of GPER to activate adenylate cyclase was illustrated as a mechanism involved in the activation and/or inhibition in ERK1/2 [<xref rid="B38-cells-08-01123" ref-type="bibr">38</xref>]. On the flip side, GPER activates the PI3K/Akt pathway and responds to 17&#x003b2;-estradiol with EGFR transactivation involved. In addition, 17&#x003b2;-estradiol can stimulate the growth of human keratinocytes by inducing cyclin D2 expression, and induce the expression of c-Fos (a cyclic adenosine monophosphate signal in macrophages) to enhance the production of nerve growth factor, which are both mediated via cell surface GPER [<xref rid="B39-cells-08-01123" ref-type="bibr">39</xref>,<xref rid="B40-cells-08-01123" ref-type="bibr">40</xref>]. In spite of rapid signaling events, GPER also regulates gene expression, such as c-fos and D1 [<xref rid="B41-cells-08-01123" ref-type="bibr">41</xref>,<xref rid="B42-cells-08-01123" ref-type="bibr">42</xref>], growth factor of connective tissue [<xref rid="B43-cells-08-01123" ref-type="bibr">43</xref>], fatty acid synthase [<xref rid="B44-cells-08-01123" ref-type="bibr">44</xref>], and vascular endothelial growth function [<xref rid="B45-cells-08-01123" ref-type="bibr">45</xref>]. All of these different GPER activation pathways regulate a variety of cellular physiology functions in proliferation, metabolism, migration, and secretion, which also shows the great influence of GPER in physiological and pathological processes. As mentioned above, ER&#x003b1; and ER&#x003b2; mediate multiple physiological processes. At the cellular level, ER&#x003b1;, ER&#x003b2;, and GPER may function synergistically or antagonistically, which means the final cellular outcome would be decided by the interaction of all activation and inhibition pathways.</p></sec><sec id="sec2dot3-cells-08-01123"><title>2.3. Estrogen Receptor Ligands</title><p>Estrogen receptor ligands and other factors affect the hormone signal transduction pathway: The modulation of endogenous ligands and coregulators can be a candidate for tumors and therapeutic targets. In addition to 17&#x003b2;-estradiol, estrogen receptor ligands can activate the receptors of each subtype, and the synthesis and use of specific ligands have received extensive attention. These compounds, SERMs, bind to these receptors with specificity in transcriptional-activation activity (for example, tamoxifen is an ER&#x003b1;-selective agonist or antagonist, and raloxifene is an ER&#x003b2;-selective agonist or antagonist). In order to study the molecular mechanisms of the action of three estrogen receptors, many synthetic selective agonists or antagonists have been successfully developed: 4,4&#x02032;,4&#x02032;&#x02019;-[4-propyl-(1H)-pyrazole-1,3,5-triyl] trisphenol (PPT) activates ER&#x003b1;, 2,3-bis (4-hydroxyphenyl)&#x02013;propionitrile (DPN) is an agonist of ER&#x003b2;, and compound G-1 is a highly specific agonist of GPR30. <xref ref-type="fig" rid="cells-08-01123-f001">Figure 1</xref> shows various estrogen receptor ligands, including endogenous and exogenous ligands, SERMs, SERDs, and GPER agonists and antagonists, which correspond to their receptors.</p></sec><sec id="sec2dot4-cells-08-01123"><title>2.4. Cell Mechanisms</title><p>Estrogen mediates its biological response through several possible cellular mechanisms, as shown in <xref ref-type="fig" rid="cells-08-01123-f002">Figure 2</xref>. There are two main cellular roles involving receptors: genomic activity and rapid nongenomic effects [<xref rid="B46-cells-08-01123" ref-type="bibr">46</xref>]. It was reported that the rapid effects take place within minutes in the process of therapy. Furthermore, by inhibiting the MAPK/ERK or AKT signaling pathway, nongenomic effects can be stopped. Initiating the processes of these signaling pathways is closely related to GPR30-mediated plasma-membrane-associated processes [<xref rid="B47-cells-08-01123" ref-type="bibr">47</xref>]. Here, we elaborate on the process of ER&#x003b1; transportation to the cell membrane and the signaling that follows. ER can bind to caveolin 1 (Cav-1) physically induced by ER&#x003b1; palmitoylation [<xref rid="B48-cells-08-01123" ref-type="bibr">48</xref>]. After the binding process, Cav-1 transports ER to the caveolae rafts in the membrane and is capable of assembling various signaling molecules [<xref rid="B49-cells-08-01123" ref-type="bibr">49</xref>]. The activation process of ER is achieved by association with G-protein &#x003b1; and &#x003b2;/&#x003b3; subunits after its linking with E2 and the following dimerization [<xref rid="B50-cells-08-01123" ref-type="bibr">50</xref>,<xref rid="B51-cells-08-01123" ref-type="bibr">51</xref>]. The activation of the G-protein can initiate multiple rapid nongenomic effects in a matter of seconds, including cyclic nucleotide production and early kinase activation. On the other hand, because of signaling to the epigenome of membrane ER and the improvement of receptor activity caused by nuclear ER protein post-translational modification, non-palmitoylated nuclear-localization ER is recruited to promoters and enhancers that regulate genes required for the regulation of steroid action. During the binding of hormones to extranuclear receptor proteins, the steroid-binding unit of the protein changes, which is called receptor transformation. Receptor transformation is an important step in the action of estrogen, and hormone-induced receptor proteins are converted into biochemically functional forms [<xref rid="B52-cells-08-01123" ref-type="bibr">52</xref>].</p><p>There are three predominant mechanisms of genomic transcriptional regulation mediated by estrogen receptors. The classical mechanism (direct binding to DNA regulatory elements) can be illustrated by the following example. Helix 12 is the functional core of AF-2 and is highly conserved in ligand-binding domains. The process of binding to a ligand can alter the configuration of helix 12, which leads to an agonistic or antagonistic form of transcriptional regulation [<xref rid="B53-cells-08-01123" ref-type="bibr">53</xref>]. Binding between ER and hormone results in a change of conformation in the ligand-binding domain that allows helix 12 to interact with coactivators. The resulting genomic reaction requires coactivator binding and is proportional to the magnitude of the reaction. On the other hand, as shown by studies at the cellular level and the living individual level, ER&#x003b1; binds to the DNA with inactive status in the absence of hormones [<xref rid="B54-cells-08-01123" ref-type="bibr">54</xref>,<xref rid="B55-cells-08-01123" ref-type="bibr">55</xref>]. A mouse model of DNA-binding domain mutation of ER&#x003b1; indicates that direct DNA binding is required to activate both biological activity and hormone response. Nuclear factors such as pro-factor FoxA1 may affect direct binding, and by recruiting chromatin at the binding site to remodel the protein, the chromatin is opened, allowing the ER to enter its regulatory DNA site. Following this, the recruitment of polymerase II initiates gene transcription after assembling the transcription complex, which is comprised of multiple components [<xref rid="B56-cells-08-01123" ref-type="bibr">56</xref>]. In the second ER-regulated mechanism, ER binds to transcription factors that are already bound to the DNA. Then, hormone receptors regulate gene expression first via the interaction between proteins and transcription factors, then, these transcription factors directly bind to their respective response elements [<xref rid="B57-cells-08-01123" ref-type="bibr">57</xref>]. As for the third mechanism, ER can regulate hormone responses without hormones through the activation of growth factors without ligands, which is attributed to the phosphorylation process of some serine residues on the receptor [<xref rid="B58-cells-08-01123" ref-type="bibr">58</xref>]. In addition to its ability to directly regulate gene expression, estrogen also affects cell signaling and cellular function through rapid membrane-initiation events. Many signaling processes rely on estrogen receptors localized to the plasma membrane. Lipid rafts are critical for ER plasma-membrane localization and play a key role in its membrane-priming effect [<xref rid="B59-cells-08-01123" ref-type="bibr">59</xref>]. Together, the integration of these cellular signaling pathways can mediate genomic activities and rapid nongenomic effects independently and/or complementarily, which activates the effects of estrogen through hormonal response.</p></sec></sec><sec id="sec3-cells-08-01123"><title>3. ERs and Female Reproductive Diseases</title><sec id="sec3dot1-cells-08-01123"><title>3.1. ERs and Ovarian Cancer</title><p>In women of childbearing age, ER&#x003b1; is mainly located at thecal cells and the ovarian stroma in the corpus luteum and surface epithelium of the ovary. In postmenopausal women, ER&#x003b1; is present in the stroma, the epithelial inclusion cyst, and the ovarian-surface epithelium. The main locations of ER&#x003b2; are granulosa cells. Growths that depend on estrogen in response to endocrine therapy for ovarian cancer are closely related to the expression level of ER&#x003b1;. ER is downregulated in ER&#x003b1;-positive ovarian cancer, while being targeted directly by tumor suppressor microRNA (miR)-206. Therefore, the introduction of miR-206 mimics could inhibit cell proliferation and the invasion of ovarian-cancer cells [<xref rid="B60-cells-08-01123" ref-type="bibr">60</xref>,<xref rid="B61-cells-08-01123" ref-type="bibr">61</xref>]. Recent studies have shown that long noncoding RNAs can mediate the function of ER&#x003b1; in ovarian cancer [<xref rid="B62-cells-08-01123" ref-type="bibr">62</xref>]. The promotion of ER&#x003b1; in ovarian cancer suggests that endocrine therapy may be an efficacious option. Unfortunately, ovarian cancer is not often treated with antiestrogenic drugs because of the low response rates. As ovarian cancer occurs, the ratio of ER&#x003b2; and/or ER&#x003b2;/ER&#x003b1; decreases, indicating that carcinogenesis may be associated with the loss of ER&#x003b2; expression. Treatment or reintroduction of ER&#x003b2; with ER&#x003b2; agonist DPN significantly inhibits the growth of ovarian cells [<xref rid="B63-cells-08-01123" ref-type="bibr">63</xref>]. It is worth noting that recent studies have shown that a normal ovarian epithelium almost completely shows ER&#x003b2; cell-nuclear positive immunity, while ovarian-cancer tissue mostly shows the cytoplasmic staining of ER&#x003b2;. Therefore, the expression of cytoplasmic ER&#x003b2; is recognized as an independent unfavorable prognostic factor [<xref rid="B64-cells-08-01123" ref-type="bibr">64</xref>]. In addition, statistical data indicate that cytoplasmic ER&#x003b2;2 (one of the isoforms of ER&#x003b2;) expression is positively correlated with five-year survival and decreased chemical resistance [<xref rid="B65-cells-08-01123" ref-type="bibr">65</xref>]. These new results suggest that different isoforms of ER&#x003b2; may function in different ways, which is possibly due to their different cellular localization and prognosis. Recent studies have shown that natural ER&#x003b2; agonists have the potential to significantly inhibit the growth of ovarian-cancer cells through anti-inflammatory and proapoptotic effects, and can be used as novel therapeutic agents for the treatment of ovarian cancer [<xref rid="B66-cells-08-01123" ref-type="bibr">66</xref>].</p></sec><sec id="sec3dot2-cells-08-01123"><title>3.2. ERs and Endometriosis</title><p>Endometriosis refers to a common gynecological disease formed by the active endometrial cells being implanted outside the endometrium [<xref rid="B67-cells-08-01123" ref-type="bibr">67</xref>]. The symptoms have a negative impact on the health and quality of life of the patient. Among all patients with endometriosis, according to statistical data, 40%&#x02013;50% have fertility problems [<xref rid="B68-cells-08-01123" ref-type="bibr">68</xref>].</p><p>Estrogen-mediated changes in cell signaling have important implications for the pathogenesis of endometriosis. The invasion and migration of endometriosis eutopic endometrial stromal cells (euESC) can be regulated by estrogen/H19/miR-216a-5p/ACTA2 pathways. Specifically, the invasion and migration of euESC can be inhibited by the suppression of H19 or ACTA2, and promoted by estrogen via H19 [<xref rid="B69-cells-08-01123" ref-type="bibr">69</xref>]. Endometriosis contains higher levels of 17&#x003b2;-estradiol than the normal endometrium because of higher levels of aromatase and 17&#x003b2;-hydroxysteroid dehydrogenase-1 genes [<xref rid="B70-cells-08-01123" ref-type="bibr">70</xref>]. High levels of 17&#x003b2;-estradiol activate ER in endometriotic tissue and stimulate growth that depends on estrogen. In endometriotic tissue, both the ER&#x003b1; and the ER&#x003b2; isoforms are required for the growth of endometriotic lesions. In mice, ER&#x003b1; knockout females are sterile because their uteruses are not sensitive to estrogen. On the contrary, ER&#x003b2; knockout females are sub-fertile and primarily lack effective ovulation function [<xref rid="B71-cells-08-01123" ref-type="bibr">71</xref>]. The important role of ER&#x003b1; and ER&#x003b2; in the development of mouse ectopic lesions have been revealed in previous research [<xref rid="B72-cells-08-01123" ref-type="bibr">72</xref>,<xref rid="B73-cells-08-01123" ref-type="bibr">73</xref>]. Functional studies on ER&#x003b2; have shown that it can prevent apoptosis, enhance adhesion, invasion, proliferation, inflammatory body activity, and inflammatory signals of ectopic lesions. Studies on ER&#x003b1; knockout mice with endometriosis have shown that ER&#x003b1; brings cell adhesion and proliferation, and regulates inflammatory signaling in ectopic lesions [<xref rid="B74-cells-08-01123" ref-type="bibr">74</xref>]. However, different isoforms of ER mean various kinds of expression patterns between types of tissue with endometriosis and a normal endometrium [<xref rid="B75-cells-08-01123" ref-type="bibr">75</xref>]. Contrary to the case of ER&#x003b1;, not only can high levels of estrogen receptors be detected in tissue with endometriosis, but also enhanced ER&#x003b2; activity. In addition, ER&#x003b2;-selective antagonists promote the inhibition of ER&#x003b2; activity and inhibit the growth of ectopic lesions in mice. It is worth noting that the acquisition of ER&#x003b2; function stimulates endometriotic processes. ER&#x003b2; inhibits TNF&#x003b1;-induced apoptosis through interactions with apoptotic mechanisms to avoid the endogenous immune surveillance of survival cells [<xref rid="B76-cells-08-01123" ref-type="bibr">76</xref>]. ER&#x003b2; also promotes the expression level of interleukin-1&#x003b2; through interactions with components of the cytoplasmic inflammatory body, thereby enhancing its cell-proliferation characteristics. In order to identify the target of ER&#x003b2; in endometriosis, a genome-wide comparative analysis method was used to identify Ras-related and estrogen-regulated growth inhibitor (RERG) and serum and glucocorticoid-regulated kinases (SGK1) [<xref rid="B77-cells-08-01123" ref-type="bibr">77</xref>,<xref rid="B78-cells-08-01123" ref-type="bibr">78</xref>]. Among them, RERG can induce the proliferation of primary endometriotic cells, and the levels of RERG mRNA and protein in human endometriotic stromal cells can be induced by estradiol. Prostaglandin E2 (PGE<sub>2</sub>) can also phosphorylate RERG. Thus, integration of ER&#x003b2; and PGE<sub>2</sub> signaling in RERG results in endometrial ectopic cell proliferation. In addition, since the expression of SGK<sub>1</sub> is stimulated by estradiol and ER&#x003b2;, the number of endometrial ectopic cells is increased [<xref rid="B79-cells-08-01123" ref-type="bibr">79</xref>]. ER&#x003b2; functions in a variety of ways to promote cell-proliferation and tissue-invasion activity in endometriosis sites to establish ectopic lesions (<xref ref-type="fig" rid="cells-08-01123-f002">Figure 2</xref>).</p><p>GPER expression in mature follicles/oocytes is more frequent than in primordial follicles/oocytes, which means that GPER may be the choice during follicular development. In addition, GPER is upregulated in ovarian endometriosis [<xref rid="B80-cells-08-01123" ref-type="bibr">80</xref>]. GPER is maximally expressed during the proliferative phase. There is overexpression of GPER in the eutopic and ectopic endometrium in patients with endometriosis compared with the eutopic endometrium of normal participants [<xref rid="B81-cells-08-01123" ref-type="bibr">81</xref>]. In addition, recent research has found and optimized pyridyl-cycloalkyl-carboxylic acids as an inhibitor of microsomal prostaglandin E synthase-1 for the treatment of endometriosis [<xref rid="B82-cells-08-01123" ref-type="bibr">82</xref>].</p></sec><sec id="sec3dot3-cells-08-01123"><title>3.3. ERs and Polycystic Ovary Syndrome</title><p>Polycystic ovary syndrome (PCOS) is a complex endocrine and metabolic abnormality, common in women of childbearing age, and is the most common female endocrine disease. It is characterized by chronic anovulation (ovulation dysfunction or loss) and hyperandrogenism (excessive male-hormone production in women). The main clinical manifestations are an irregular menstrual cycle, infertility, hairiness, and/or acne [<xref rid="B83-cells-08-01123" ref-type="bibr">83</xref>,<xref rid="B84-cells-08-01123" ref-type="bibr">84</xref>]. PCOS is associated with global and gene-specific DNA methylation remodeling in a cell-type-specific manner [<xref rid="B85-cells-08-01123" ref-type="bibr">85</xref>]. Furthermore, PCOS is an important risk factor for type 2 diabetes, cardiovascular disease, gestational diabetes, pregnancy-induced hypertension, and endometrial cancer [<xref rid="B86-cells-08-01123" ref-type="bibr">86</xref>]. Studies have shown that the endometrial phenotype and dysfunction of women with PCOS are abnormal. PCOS women are at least three times more likely to develop endometrial cancer (EC) [<xref rid="B87-cells-08-01123" ref-type="bibr">87</xref>,<xref rid="B88-cells-08-01123" ref-type="bibr">88</xref>]. Endometrial cancer is associated with endometrial hyperplasia, no antagonistic estrogenic effects and genetic alterations, and is classically classified into two types: type I, which is the most prevalent and estrogen-dependent, and type II, which is more aggressive and generally considered to be estrogen-independent.</p><p>In a normal menstrual cycle, the life cycle of the endometrium is divided into a proliferative phase and a secretory phase. It is based on the response of the endometrium to steroid hormones (progesterone, androgen, and estrogen) up- or down-regulated [<xref rid="B89-cells-08-01123" ref-type="bibr">89</xref>]. The main cell types that steroid hormones target in the endometrium are epithelial cells and stromal cells. The activity of mitosis and extensive proliferation activated by estrogen are two main characteristics of the proliferative phase, and elevated estrogen promotes expression levels of ER&#x003b1; and ER&#x003b2;, which are the highest in the late phase of proliferation [<xref rid="B90-cells-08-01123" ref-type="bibr">90</xref>,<xref rid="B91-cells-08-01123" ref-type="bibr">91</xref>]. Estradiol increases the expression of progesterone receptors mainly through ER&#x003b1; activation, thereby causing the action of progesterone on the endometrium, and triggering the secretory phase of endometrial circulation. In contrast, progesterone inhibits ER expression on the endometrium and inhibits estrogenic effects, thereby initiating endometrial reprogramming and inducing interstitial differentiation. In recent years, studies have demonstrated that several endometrial features associated with the PCOS phenotype may explain the clinical manifestations that are related to an adverse endometrium. ER is the most prominent endometrial marker in women with PCOS. A study showed that expression of ER was increased in the stroma and glandular epithelium of PCOS women when compared to a normal endometrium [<xref rid="B92-cells-08-01123" ref-type="bibr">92</xref>,<xref rid="B93-cells-08-01123" ref-type="bibr">93</xref>]. However, in two relatively advanced studies, gene-expression differences between female endometrial samples in PCOS and control groups were reported, and no changes in ER expression were found [<xref rid="B94-cells-08-01123" ref-type="bibr">94</xref>,<xref rid="B95-cells-08-01123" ref-type="bibr">95</xref>]. Studies have also shown that the expression of p160 steroid receptor coactivator is increased in the endometrium of PCOS women, which may promote the activation of ER&#x003b1; and regulate estrogen effects [<xref rid="B92-cells-08-01123" ref-type="bibr">92</xref>,<xref rid="B93-cells-08-01123" ref-type="bibr">93</xref>]. In short, an abnormal steroid environment may alter endometrial receptivity in these women.</p><p>At present, drug treatment of PCOS has replaced surgical treatment as the preferred treatment, and the treatment route is mainly related to the patient&#x02019;s fertility requirements. PCOS can be treated by reducing hyperandrogenism by using oral contraceptives, glucocorticoids, spironolactone, and fluorinated amides. PCOS patients with fertility requirements need to use ovulation-induction therapy to prevent pregnancy. There has been great progress on drugs for ovulation induction in the past 50 years. Clomiphene is the first choice, which can bind to the hypothalamic estrogen receptor, causing the central nervous system to block estrogen levels in circulation, and pulsed GnRH and gonadotropin secretion are increased, further causing follicular growth and development. In addition, clomiphene can directly affect the pituitary and ovaries, respectively, increase gonadotropin secretion, synergistically enhancing FSH-induced aromatase activity. Clomiphene also exhibits antiestrogenic properties in other parts of the female reproductive tract, especially the endometrium and cervix.</p><p>In adolescent populations, the pathophysiology of PCOS is multifactorial. Medical therapy includes combined hormonal contraceptives spironolactone and metformin [<xref rid="B96-cells-08-01123" ref-type="bibr">96</xref>], oral contraceptive pills, and local treatments for hirsutism and acne [<xref rid="B97-cells-08-01123" ref-type="bibr">97</xref>]. The latest research showed that aromatase expression may be affected by epigenetic modifications and the binding of differential ER&#x003b2; to the proximal CYP19A1 promoter, possibly involved in enhanced aromatase transcription during ovarian stimulation in PCOS patients [<xref rid="B98-cells-08-01123" ref-type="bibr">98</xref>].</p></sec></sec><sec id="sec4-cells-08-01123"><title>4. Therapeutic Drugs</title><p>In current therapeutic strategies, a variety of nonsteroidal compounds (with agonist or antagonist activity) and synthetic estrogen derivatives have been developed corresponding to different clinical symptoms and needs. As mentioned above, the ligand-binding domains of ER&#x003b1; and ER&#x003b2; show a high level of homology, but tissue distribution and the physiological effects are very different. The discovery of GPER further complicates ligand-binding selectivity, affinity, and differences in the types of responses mediated by estrogen-receptor subtypes and classes. Successfully researched and developed selective agonists and antagonists make it easier to distinguish between subtypes of ER&#x003b1;, ER&#x003b2;, and GPER. Moreover, this has provided a more powerful tool for research and has optimized existing treatments. Some examples are shown below (<xref ref-type="fig" rid="cells-08-01123-f003">Figure 3</xref>).</p><p>The simple structure of the phenolic stilbene compound diethylstilbestrol (DES) has a binding affinity for ER&#x003b1;/&#x003b2; that is about four times higher than that of E2 [<xref rid="B99-cells-08-01123" ref-type="bibr">99</xref>]. The selective ER&#x003b1;/&#x003b2; of DES has been used in research to distinguish between ER&#x003b1;/&#x003b2;-mediated biological responses.</p><p>Tamoxifen was originally developed for contraceptive use, but is now used as adjuvant antiestrogen treatment for the therapy of early and late ER&#x003b1;-positive breast tumors in premenopausal and postmenopausal women [<xref rid="B100-cells-08-01123" ref-type="bibr">100</xref>].</p><p>Raloxifene (Evista) is a phenolic benzothiophene benzoketone substituted with an alkaline piperidin-1-ylethoxy side chain that acts as a SERM relative to ER&#x003b1;/&#x003b2;. Raloxifene can elicit estrogen on bone; this characteristic leads to the treatment of osteoporosis in postmenopausal women, and the antiestrogen effects of raloxifene in breasts and the uterus have been shown to effectively reduce the incidence of breast cancer, and reduce uterine-cancer and thrombosis risk. Raloxifene exhibits strong GPER efficacy as a GPER agonist [<xref rid="B101-cells-08-01123" ref-type="bibr">101</xref>].</p><p>17&#x003b1;-ethynyl-17&#x003b2;-estradiol (also known as ethinyl estradiol) is a synthetic estrogen used in oral contraceptives because of its prolonged biological activity in vivo, and ability to reduce the metabolism. The affinity of ethinyl estradiol for ER&#x003b1;/&#x003b2; is approximately twice that of 17&#x003b2;-estradiol [<xref rid="B102-cells-08-01123" ref-type="bibr">102</xref>].</p></sec><sec id="sec5-cells-08-01123"><title>5. Concluding Remarks</title><p>This article details the regulation and mechanisms of estrogen, and its nuclear and membrane receptors, the latest advances in diseases caused by the abnormal expression of estrogen and its receptors in the ovary, and related targeted therapeutic drugs applied in clinical research and treatment. Estrogen and its receptors play a key role in the pathophysiology of various systems in the human body. In this review, we highlighted their mechanisms of action and related diseases in the female reproductive system (mainly ovarian cancer, PCOS, and EMS). Research on these three ER-related diseases is still ongoing, and some of the latest research results also reveal the pathophysiology of the disease step by step. Based on the ongoing research progress, more clinical drugs with more effective and minimal side effects will be developed and applied. Studies of estrogen receptors have been ongoing for more than 50 years, and this brief review can only provide a measurable overview of the broad knowledge of these receptors. We hope to provide a reference for the treatment of female ovarian diseases.</p></sec></body><back><notes><title>Author Contributions</title><p>S.-L.D., K.Y., R.Z., Z.-X.L., and Z.-R.T. wrote the paper.</p></notes><notes><title>Funding</title><p>This work was supported by the National Transgenic Creature Breeding Grand Project (2016zx08008-003).</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-cells-08-01123"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Callard</surname><given-names>G.V.</given-names></name><name><surname>Tarrant</surname><given-names>A.M.</given-names></name><name><surname>Novillo</surname><given-names>A.</given-names></name><name><surname>Yacci</surname><given-names>P.</given-names></name><name><surname>Ciaccia</surname><given-names>L.</given-names></name><name><surname>Vajda</surname><given-names>S.</given-names></name><name><surname>Chuang</surname><given-names>G.</given-names></name><name><surname>Kozakov</surname><given-names>D.</given-names></name><name><surname>Greytak</surname><given-names>S.R.</given-names></name><name><surname>Sawyer</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Evolutionary origins of the estrogen signaling system: Insights from amphioxus</article-title><source>J. Steroid Biochem. Mol. Biol.</source><year>2011</year><volume>127</volume><fpage>176</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1016/j.jsbmb.2011.03.022</pub-id><?supplied-pmid 21514383?><pub-id pub-id-type="pmid">21514383</pub-id></element-citation></ref><ref id="B2-cells-08-01123"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>E.V.</given-names></name><name><surname>Jacobson</surname><given-names>H.I.</given-names></name></person-group><article-title>Basic guides to the mechanism of. Estrogen action</article-title><source>Recent Progr. Hormone Res.</source><year>1962</year><volume>18</volume></element-citation></ref><ref id="B3-cells-08-01123"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuiper</surname><given-names>G.G.</given-names></name><name><surname>Enmark</surname><given-names>E.</given-names></name><name><surname>Pelto-Huikko</surname><given-names>M.</given-names></name><name><surname>Nilsson</surname><given-names>S.</given-names></name><name><surname>Gustafsson</surname><given-names>J.A.</given-names></name></person-group><article-title>Cloning of a novel receptor expressed in rat prostate and ovary</article-title><source>P. Natl. Acad. Sci. USA</source><year>1996</year><volume>93</volume><fpage>5925</fpage><lpage>5930</lpage><pub-id pub-id-type="doi">10.1073/pnas.93.12.5925</pub-id><?supplied-pmid 8650195?><pub-id pub-id-type="pmid">8650195</pub-id></element-citation></ref><ref id="B4-cells-08-01123"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>P.</given-names></name><name><surname>Pang</surname><given-names>Y.</given-names></name><name><surname>Filardo</surname><given-names>E.J.</given-names></name><name><surname>Dong</surname><given-names>J.</given-names></name></person-group><article-title>Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells</article-title><source>Endocrinology</source><year>2005</year><volume>146</volume><fpage>624</fpage><lpage>632</lpage><pub-id pub-id-type="doi">10.1210/en.2004-1064</pub-id><?supplied-pmid 15539556?><pub-id pub-id-type="pmid">15539556</pub-id></element-citation></ref><ref id="B5-cells-08-01123"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Revankar</surname><given-names>C.M.</given-names></name><name><surname>Cimino</surname><given-names>D.F.</given-names></name><name><surname>Sklar</surname><given-names>L.A.</given-names></name><name><surname>Arterburn</surname><given-names>J.B.</given-names></name><name><surname>Prossnitz</surname><given-names>E.R.</given-names></name></person-group><article-title>A transmembrane intracellular estrogen receptor mediates rapid cell signaling</article-title><source>Science</source><year>2005</year><volume>307</volume><fpage>1625</fpage><lpage>1630</lpage><pub-id pub-id-type="doi">10.1126/science.1106943</pub-id><?supplied-pmid 15705806?><pub-id pub-id-type="pmid">15705806</pub-id></element-citation></ref><ref id="B6-cells-08-01123"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burris</surname><given-names>T.P.</given-names></name><name><surname>Solt</surname><given-names>L.A.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Crumbley</surname><given-names>C.</given-names></name><name><surname>Banerjee</surname><given-names>S.</given-names></name><name><surname>Griffett</surname><given-names>K.</given-names></name><name><surname>Lundasen</surname><given-names>T.</given-names></name><name><surname>Hughes</surname><given-names>T.</given-names></name><name><surname>Kojetin</surname><given-names>D.J.</given-names></name></person-group><article-title>Nuclear receptors and their selective pharmacologic modulators</article-title><source>Pharmacol. Rev.</source><year>2013</year><volume>65</volume><fpage>710</fpage><lpage>778</lpage><pub-id pub-id-type="doi">10.1124/pr.112.006833</pub-id><pub-id pub-id-type="pmid">23457206</pub-id></element-citation></ref><ref id="B7-cells-08-01123"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barton</surname><given-names>M.</given-names></name><name><surname>Prossnitz</surname><given-names>E.R.</given-names></name></person-group><article-title>Emerging roles of GPER in diabetes and atherosclerosis</article-title><source>Trends Endocrinol. Metab.</source><year>2015</year><volume>26</volume><fpage>185</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1016/j.tem.2015.02.003</pub-id><?supplied-pmid 25767029?><pub-id pub-id-type="pmid">25767029</pub-id></element-citation></ref><ref id="B8-cells-08-01123"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lappano</surname><given-names>R.</given-names></name><name><surname>Pisano</surname><given-names>A.</given-names></name><name><surname>Maggiolini</surname><given-names>M.</given-names></name></person-group><article-title>GPER Function in Breast Cancer: An Overview</article-title><source>Front Endocrinol.</source><year>2014</year><volume>5</volume><fpage>66</fpage><pub-id pub-id-type="doi">10.3389/fendo.2014.00066</pub-id></element-citation></ref><ref id="B9-cells-08-01123"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prossnitz</surname><given-names>E.R.</given-names></name><name><surname>Barton</surname><given-names>M.</given-names></name></person-group><article-title>Estrogen biology: New insights into GPER function and clinical opportunities</article-title><source>Mol. Cell Endocrinol.</source><year>2014</year><volume>389</volume><fpage>71</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1016/j.mce.2014.02.002</pub-id><pub-id pub-id-type="pmid">24530924</pub-id></element-citation></ref><ref id="B10-cells-08-01123"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prossnitz</surname><given-names>E.R.</given-names></name><name><surname>Barton</surname><given-names>M.</given-names></name></person-group><article-title>The G-protein-coupled estrogen receptor GPER in health and disease</article-title><source>Nat. Rev. Endocrinol.</source><year>2011</year><volume>7</volume><fpage>715</fpage><lpage>726</lpage><pub-id pub-id-type="doi">10.1038/nrendo.2011.122</pub-id><pub-id pub-id-type="pmid">21844907</pub-id></element-citation></ref><ref id="B11-cells-08-01123"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casals-Casas</surname><given-names>C.</given-names></name><name><surname>Desvergne</surname><given-names>B.</given-names></name></person-group><article-title>Endocrine disruptors: From endocrine to metabolic disruption</article-title><source>Annu. Rev. Physiol.</source><year>2011</year><volume>73</volume><fpage>135</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1146/annurev-physiol-012110-142200</pub-id><?supplied-pmid 21054169?><pub-id pub-id-type="pmid">21054169</pub-id></element-citation></ref><ref id="B12-cells-08-01123"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciruelos</surname><given-names>E.</given-names></name><name><surname>Pascual</surname><given-names>T.</given-names></name><name><surname>Arroyo</surname><given-names>V.M.</given-names></name><name><surname>Blanco</surname><given-names>M.</given-names></name><name><surname>Manso</surname><given-names>L.</given-names></name><name><surname>Parrilla</surname><given-names>L.</given-names></name><name><surname>Munoz</surname><given-names>C.</given-names></name><name><surname>Vega</surname><given-names>E.</given-names></name><name><surname>Calderon</surname><given-names>M.J.</given-names></name><name><surname>Sancho</surname><given-names>B.</given-names></name><etal/></person-group><article-title>The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer</article-title><source>Breast</source><year>2014</year><volume>23</volume><fpage>201</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1016/j.breast.2014.01.016</pub-id><?supplied-pmid 24589524?><pub-id pub-id-type="pmid">24589524</pub-id></element-citation></ref><ref id="B13-cells-08-01123"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riggs</surname><given-names>B.L.</given-names></name><name><surname>Hartmann</surname><given-names>L.C.</given-names></name></person-group><article-title>Selective estrogen-receptor modulators&#x02014;mechanisms of action and application toclinical practice</article-title><source>N. Engl. J. Med.</source><year>2003</year><volume>348</volume><fpage>618</fpage><lpage>629</lpage><pub-id pub-id-type="doi">10.1056/NEJMra022219</pub-id><?supplied-pmid 12584371?><pub-id pub-id-type="pmid">12584371</pub-id></element-citation></ref><ref id="B14-cells-08-01123"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>M.</given-names></name><name><surname>Dahlman-Wright</surname><given-names>K.</given-names></name><name><surname>Gustafsson</surname><given-names>J.</given-names></name></person-group><article-title>Estrogen receptor alpha and beta in health and disease</article-title><source>Best Pract. Res. Clin. Haematol.</source><year>2015</year><volume>29</volume><fpage>557</fpage><lpage>568</lpage><pub-id pub-id-type="doi">10.1016/j.beem.2015.04.008</pub-id><?supplied-pmid 26303083?><pub-id pub-id-type="pmid">26303083</pub-id></element-citation></ref><ref id="B15-cells-08-01123"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamilton</surname><given-names>K.J.</given-names></name><name><surname>Hewitt</surname><given-names>S.C.</given-names></name><name><surname>Arao</surname><given-names>Y.</given-names></name><name><surname>Korach</surname><given-names>K.S.</given-names></name></person-group><article-title>Estrogen Hormone Biology</article-title><source>Curr. Top Dev. Biol.</source><year>2017</year><volume>125</volume><fpage>109</fpage><lpage>146</lpage><?supplied-pmid 28527569?><pub-id pub-id-type="pmid">28527569</pub-id></element-citation></ref><ref id="B16-cells-08-01123"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mangelsdorf</surname><given-names>D.J.</given-names></name><name><surname>Thummel</surname><given-names>C.</given-names></name><name><surname>Beato</surname><given-names>M.</given-names></name><name><surname>Herrlich</surname><given-names>P.</given-names></name><name><surname>Sch&#x000fc;tz</surname><given-names>G.</given-names></name><name><surname>Umesono</surname><given-names>K.</given-names></name><name><surname>Blumberg</surname><given-names>B.</given-names></name><name><surname>Kastner</surname><given-names>P.</given-names></name><name><surname>Mark</surname><given-names>M.</given-names></name><name><surname>Chambon</surname><given-names>P.</given-names></name><etal/></person-group><article-title>The nuclear receptor superfamily: The second decade</article-title><source>Cell</source><year>1995</year><volume>83</volume><fpage>835</fpage><lpage>839</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(95)90199-X</pub-id><pub-id pub-id-type="pmid">8521507</pub-id></element-citation></ref><ref id="B17-cells-08-01123"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eyster</surname><given-names>K.M.</given-names></name></person-group><article-title>The Estrogen Receptors: An Overview from Different Perspectives</article-title><source>Methods Mol. Biol.</source><year>2016</year><volume>1366</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">26585122</pub-id></element-citation></ref><ref id="B18-cells-08-01123"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Germain</surname><given-names>P.</given-names></name><name><surname>Staels</surname><given-names>B.</given-names></name><name><surname>Dacquet</surname><given-names>C.</given-names></name><name><surname>Spedding</surname><given-names>M.</given-names></name><name><surname>Laudet</surname><given-names>V.</given-names></name></person-group><article-title>Overview of nomenclature of nuclear receptors</article-title><source>Pharmacol. Rev.</source><year>2006</year><volume>58</volume><fpage>685</fpage><lpage>704</lpage><pub-id pub-id-type="doi">10.1124/pr.58.4.2</pub-id><pub-id pub-id-type="pmid">17132848</pub-id></element-citation></ref><ref id="B19-cells-08-01123"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bourguet</surname><given-names>W.</given-names></name><name><surname>Germain</surname><given-names>P.</given-names></name><name><surname>Gronemeyer</surname><given-names>H.</given-names></name></person-group><article-title>Nuclear receptor ligand-binding domains: Three-dimensional structures, molecular interactions and pharmacological implications</article-title><source>Trends Pharmacol. Sci.</source><year>2000</year><volume>21</volume><fpage>381</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1016/S0165-6147(00)01548-0</pub-id><pub-id pub-id-type="pmid">11050318</pub-id></element-citation></ref><ref id="B20-cells-08-01123"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hager</surname><given-names>G.L.</given-names></name><name><surname>Lim</surname><given-names>C.S.</given-names></name><name><surname>Elbi</surname><given-names>C.</given-names></name><name><surname>Baumann</surname><given-names>C.T.</given-names></name></person-group><article-title>Trafficking of nuclear receptors in living cells</article-title><source>J. Steroid Biochem. Mol. Biol.</source><year>2000</year><volume>74</volume><fpage>249</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1016/S0960-0760(00)00100-X</pub-id><pub-id pub-id-type="pmid">11162932</pub-id></element-citation></ref><ref id="B21-cells-08-01123"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evinger</surname><given-names>A.J.R.</given-names></name><name><surname>Levin</surname><given-names>E.R.</given-names></name></person-group><article-title>Requirements for estrogen receptor alpha membrane localization and function</article-title><source>Steroids</source><year>2005</year><volume>70</volume><fpage>361</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.1016/j.steroids.2005.02.015</pub-id><?supplied-pmid 15862818?><pub-id pub-id-type="pmid">15862818</pub-id></element-citation></ref><ref id="B22-cells-08-01123"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>E.R.</given-names></name><name><surname>Wardell</surname><given-names>S.E.</given-names></name><name><surname>McDonnell</surname><given-names>D.P.</given-names></name></person-group><article-title>The molecular mechanisms underlying the pharmacological actions of estrogens, SERMs and oxysterols: Implications for the treatment and prevention of osteoporosis</article-title><source>Bone</source><year>2013</year><volume>53</volume><fpage>42</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/j.bone.2012.11.011</pub-id><?supplied-pmid 23168292?><pub-id pub-id-type="pmid">23168292</pub-id></element-citation></ref><ref id="B23-cells-08-01123"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>C.L.</given-names></name><name><surname>O&#x02019;Malley</surname><given-names>B.W.</given-names></name></person-group><article-title>Coregulator function: A key to understanding tissue specificity of selectivereceptor modulators</article-title><source>Endocr. Rev.</source><year>2004</year><volume>25</volume><fpage>45</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1210/er.2003-0023</pub-id><?supplied-pmid 14769827?><pub-id pub-id-type="pmid">14769827</pub-id></element-citation></ref><ref id="B24-cells-08-01123"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dahlman-Wright</surname><given-names>K.</given-names></name><name><surname>Cavailles</surname><given-names>V.</given-names></name><name><surname>Fuqua</surname><given-names>S.A.</given-names></name><name><surname>Jordan</surname><given-names>V.C.</given-names></name><name><surname>Katzenellenbogen</surname><given-names>J.A.</given-names></name><name><surname>Korach</surname><given-names>K.S.</given-names></name><name><surname>Maggi</surname><given-names>A.</given-names></name><name><surname>Muramatsu</surname><given-names>M.</given-names></name><name><surname>Parker</surname><given-names>M.G.</given-names></name><name><surname>Gustafsson</surname><given-names>J.</given-names></name></person-group><article-title>International Union of Pharmacology. LXIV. Estrogen receptors</article-title><source>Pharmacol. Rev.</source><year>2006</year><volume>58</volume><fpage>773</fpage><lpage>781</lpage><pub-id pub-id-type="doi">10.1124/pr.58.4.8</pub-id><?supplied-pmid 17132854?><pub-id pub-id-type="pmid">17132854</pub-id></element-citation></ref><ref id="B25-cells-08-01123"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charn</surname><given-names>T.H.</given-names></name><name><surname>Liu</surname><given-names>E.T.</given-names></name><name><surname>Chang</surname><given-names>E.C.</given-names></name><name><surname>Lee</surname><given-names>Y.K.</given-names></name><name><surname>Katzenellenbogen</surname><given-names>J.A.</given-names></name><name><surname>Katzenellenbogen</surname><given-names>B.S.</given-names></name></person-group><article-title>Genome-wide dynamics of chromatin binding of estrogen receptors alpha and beta:mutual restriction and competitive site selection</article-title><source>Mol. Endocrinol.</source><year>2010</year><volume>24</volume><fpage>47</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1210/me.2009-0252</pub-id><?supplied-pmid 19897598?><pub-id pub-id-type="pmid">19897598</pub-id></element-citation></ref><ref id="B26-cells-08-01123"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prossnitz</surname><given-names>E.R.</given-names></name><name><surname>Arterburn</surname><given-names>J.B.</given-names></name><name><surname>Sklar</surname><given-names>L.A.</given-names></name></person-group><article-title>GPR30: A G protein-coupled receptor for estrogen</article-title><source>Mol. Cell Endocrinol.</source><year>2007</year><volume>265&#x02013;266</volume><fpage>138</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1016/j.mce.2006.12.010</pub-id><?supplied-pmid 17222505?><pub-id pub-id-type="pmid">17222505</pub-id></element-citation></ref><ref id="B27-cells-08-01123"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexander</surname><given-names>S.P.H.</given-names></name><name><surname>Benson</surname><given-names>H.E.</given-names></name><name><surname>Faccenda</surname><given-names>E.</given-names></name><name><surname>Pawson</surname><given-names>A.J.</given-names></name><name><surname>Sharman</surname><given-names>J.L.</given-names></name><name><surname>McGrath</surname><given-names>J.C.</given-names></name><name><surname>Catterall</surname><given-names>W.A.</given-names></name><name><surname>Spedding</surname><given-names>M.</given-names></name><name><surname>Peters</surname><given-names>J.A.</given-names></name><name><surname>Harmar</surname><given-names>A.J.</given-names></name><etal/></person-group><article-title>The Concise Guide to PHARMACOLOGY 2013/14: Overview</article-title><source>Brit. J. Pharmacol.</source><year>2013</year><volume>170</volume><fpage>1449</fpage><lpage>1458</lpage><pub-id pub-id-type="doi">10.1111/bph.12444</pub-id><?supplied-pmid 24528237?><pub-id pub-id-type="pmid">24528237</pub-id></element-citation></ref><ref id="B28-cells-08-01123"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>K.J.</given-names></name><name><surname>Liao</surname><given-names>J.K.</given-names></name></person-group><article-title>Nonnuclear actions of estrogen</article-title><source>Arterioscler. Thromb. Vasc. Biol.</source><year>2002</year><volume>22</volume><fpage>1952</fpage><lpage>1961</lpage><pub-id pub-id-type="doi">10.1161/01.ATV.0000041200.85946.4A</pub-id><pub-id pub-id-type="pmid">12482819</pub-id></element-citation></ref><ref id="B29-cells-08-01123"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gurevich</surname><given-names>E.V.</given-names></name><name><surname>Tesmer</surname><given-names>J.J.G.</given-names></name><name><surname>Mushegian</surname><given-names>A.</given-names></name><name><surname>Gurevich</surname><given-names>V.V.</given-names></name></person-group><article-title>G protein-coupled receptor kinases: More than just kinases and not only forGPCRs</article-title><source>Pharmacol. Therapeut.</source><year>2012</year><volume>133</volume><fpage>40</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2011.08.001</pub-id></element-citation></ref><ref id="B30-cells-08-01123"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terasawa</surname><given-names>E.</given-names></name><name><surname>Noel</surname><given-names>S.D.</given-names></name><name><surname>Keen</surname><given-names>K.L.</given-names></name></person-group><article-title>Rapid action of oestrogen in luteinising hormone-releasing hormone neurones: The role of GPR30</article-title><source>J. Neuroendocrinol.</source><year>2009</year><volume>21</volume><fpage>316</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2826.2009.01839.x</pub-id><pub-id pub-id-type="pmid">19207808</pub-id></element-citation></ref><ref id="B31-cells-08-01123"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liverman</surname><given-names>C.S.</given-names></name><name><surname>Brown</surname><given-names>J.W.</given-names></name><name><surname>Sandhir</surname><given-names>R.</given-names></name><name><surname>McCarson</surname><given-names>K.E.</given-names></name><name><surname>Berman</surname><given-names>N.E.J.</given-names></name></person-group><article-title>Role of the oestrogen receptors GPR30 and ERalpha in peripheral sensitization:relevance to trigeminal pain disorders in women</article-title><source>Cephalalgia</source><year>2009</year><volume>29</volume><fpage>729</fpage><lpage>741</lpage><pub-id pub-id-type="doi">10.1111/j.1468-2982.2008.01789.x</pub-id><?supplied-pmid 19220308?><pub-id pub-id-type="pmid">19220308</pub-id></element-citation></ref><ref id="B32-cells-08-01123"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuda</surname><given-names>K.</given-names></name><name><surname>Sakamoto</surname><given-names>H.</given-names></name><name><surname>Mori</surname><given-names>H.</given-names></name><name><surname>Hosokawa</surname><given-names>K.</given-names></name><name><surname>Kawamura</surname><given-names>A.</given-names></name><name><surname>Itose</surname><given-names>M.</given-names></name><name><surname>Nishi</surname><given-names>M.</given-names></name><name><surname>Prossnitz</surname><given-names>E.R.</given-names></name><name><surname>Kawata</surname><given-names>M.</given-names></name></person-group><article-title>Expression and intracellular distribution of the G protein-coupled receptor 30 inrat hippocampal formation</article-title><source>Neurosci. Lett.</source><year>2008</year><volume>441</volume><fpage>94</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2008.05.108</pub-id><?supplied-pmid 18586395?><pub-id pub-id-type="pmid">18586395</pub-id></element-citation></ref><ref id="B33-cells-08-01123"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pupo</surname><given-names>M.</given-names></name><name><surname>Vivacqua</surname><given-names>A.</given-names></name><name><surname>Perrotta</surname><given-names>I.</given-names></name><name><surname>Pisano</surname><given-names>A.</given-names></name><name><surname>Aquila</surname><given-names>S.</given-names></name><name><surname>Abonante</surname><given-names>S.</given-names></name><name><surname>Gasperi-Campani</surname><given-names>A.</given-names></name><name><surname>Pezzi</surname><given-names>V.</given-names></name><name><surname>Maggiolini</surname><given-names>M.</given-names></name></person-group><article-title>The nuclear localization signal is required for nuclear GPER translocation andfunction in breast Cancer-Associated Fibroblasts (CAFs)</article-title><source>Mol. Cell Endocrinol.</source><year>2013</year><volume>376</volume><fpage>23</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/j.mce.2013.05.023</pub-id><?supplied-pmid 23748028?><pub-id pub-id-type="pmid">23748028</pub-id></element-citation></ref><ref id="B34-cells-08-01123"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madeo</surname><given-names>A.</given-names></name><name><surname>Maggiolini</surname><given-names>M.</given-names></name></person-group><article-title>Nuclear alternate estrogen receptor GPR30 mediates 17beta-estradiol-induced gene expression and migration in breast cancer-associated fibroblasts</article-title><source>Cancer Res.</source><year>2010</year><volume>70</volume><fpage>6036</fpage><lpage>6046</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-0408</pub-id><?supplied-pmid 20551055?><pub-id pub-id-type="pmid">20551055</pub-id></element-citation></ref><ref id="B35-cells-08-01123"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Filardo</surname><given-names>E.J.</given-names></name><name><surname>Quinn</surname><given-names>J.A.</given-names></name><name><surname>Bland</surname><given-names>K.I.</given-names></name><name><surname>Frackelton</surname><given-names>A.R.J.</given-names></name></person-group><article-title>Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupledreceptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF</article-title><source>Mol. Endocrinol.</source><year>2000</year><volume>14</volume><fpage>1649</fpage><lpage>1660</lpage><pub-id pub-id-type="doi">10.1210/mend.14.10.0532</pub-id><?supplied-pmid 11043579?><pub-id pub-id-type="pmid">11043579</pub-id></element-citation></ref><ref id="B36-cells-08-01123"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelly</surname><given-names>M.J.</given-names></name><name><surname>Levin</surname><given-names>E.R.</given-names></name></person-group><article-title>Rapid actions of plasma membrane estrogen receptors</article-title><source>Trends Endocrinol. Metab.</source><year>2001</year><volume>12</volume><fpage>152</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1016/S1043-2760(01)00377-0</pub-id><pub-id pub-id-type="pmid">11295570</pub-id></element-citation></ref><ref id="B37-cells-08-01123"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Filardo</surname><given-names>E.J.</given-names></name><name><surname>Quinn</surname><given-names>J.A.</given-names></name><name><surname>Frackelton</surname><given-names>A.R.J.</given-names></name><name><surname>Bland</surname><given-names>K.I.</given-names></name></person-group><article-title>Estrogen action via the G protein-coupled receptor, GPR30: stimulation ofadenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factorreceptor-to-MAPK signaling axis</article-title><source>Mol. Endocrinol. (Baltimore, Md.)</source><year>2002</year><volume>16</volume><fpage>70</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1210/mend.16.1.0758</pub-id></element-citation></ref><ref id="B38-cells-08-01123"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindsey</surname><given-names>S.H.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Chappell</surname><given-names>M.C.</given-names></name></person-group><article-title>Vasodilation by GPER in mesenteric arteries involves both endothelial nitricoxide and smooth muscle cAMP signaling</article-title><source>Steroids</source><year>2014</year><volume>81</volume><fpage>99</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1016/j.steroids.2013.10.017</pub-id><pub-id pub-id-type="pmid">24246735</pub-id></element-citation></ref><ref id="B39-cells-08-01123"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanda</surname><given-names>N.</given-names></name><name><surname>Watanabe</surname><given-names>S.</given-names></name></person-group><article-title>17beta-estradiol stimulates the growth of human keratinocytes by inducing cyclin D2 expression</article-title><source>J. Investig. Dermatol.</source><year>2004</year><volume>123</volume><fpage>319</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1111/j.0022-202X.2004.12645.x</pub-id><pub-id pub-id-type="pmid">15245432</pub-id></element-citation></ref><ref id="B40-cells-08-01123"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanda</surname><given-names>N.</given-names></name><name><surname>Watanabe</surname><given-names>S.</given-names></name></person-group><article-title>17Beta-estradiol enhances the production of nerve growth factor in THP-1-derived macrophages or peripheral blood monocyte-derived macrophages</article-title><source>J. Investig. Dermatol.</source><year>2003</year><volume>121</volume><fpage>771</fpage><lpage>780</lpage><pub-id pub-id-type="doi">10.1046/j.1523-1747.2003.12487.x</pub-id><pub-id pub-id-type="pmid">14632195</pub-id></element-citation></ref><ref id="B41-cells-08-01123"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albanito</surname><given-names>L.</given-names></name><name><surname>Lappano</surname><given-names>R.</given-names></name><name><surname>Madeo</surname><given-names>A.</given-names></name><name><surname>Chimento</surname><given-names>A.</given-names></name><name><surname>Prossnitz</surname><given-names>E.R.</given-names></name><name><surname>Cappello</surname><given-names>A.R.</given-names></name><name><surname>Dolce</surname><given-names>V.</given-names></name><name><surname>Abonante</surname><given-names>S.</given-names></name><name><surname>Pezzi</surname><given-names>V.</given-names></name><name><surname>Maggiolini</surname><given-names>M.</given-names></name></person-group><article-title>Effects of atrazine on estrogen receptor alpha- and G protein-coupled receptor30-mediated signaling and proliferation in cancer cells and cancer-associatedfibroblasts</article-title><source>Environ. Health Persp.</source><year>2015</year><volume>123</volume><fpage>493</fpage><lpage>499</lpage><pub-id pub-id-type="doi">10.1289/ehp.1408586</pub-id><?supplied-pmid 25616260?><pub-id pub-id-type="pmid">25616260</pub-id></element-citation></ref><ref id="B42-cells-08-01123"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vivacqua</surname><given-names>A.</given-names></name><name><surname>Bonofiglio</surname><given-names>D.</given-names></name><name><surname>Albanito</surname><given-names>L.</given-names></name><name><surname>Madeo</surname><given-names>A.</given-names></name><name><surname>Rago</surname><given-names>V.</given-names></name><name><surname>Carpino</surname><given-names>A.</given-names></name><name><surname>Musti</surname><given-names>A.M.</given-names></name><name><surname>Picard</surname><given-names>D.</given-names></name><name><surname>Ando</surname><given-names>S.</given-names></name><name><surname>Maggiolini</surname><given-names>M.</given-names></name></person-group><article-title>17beta-estradiol, genistein, and 4-hydroxytamoxifen induce the proliferation ofthyroid cancer cells through the g protein-coupled receptor GPR30</article-title><source>Mol. Pharmacol.</source><year>2006</year><volume>70</volume><fpage>1414</fpage><lpage>1423</lpage><pub-id pub-id-type="doi">10.1124/mol.106.026344</pub-id><?supplied-pmid 16835357?><pub-id pub-id-type="pmid">16835357</pub-id></element-citation></ref><ref id="B43-cells-08-01123"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albanito</surname><given-names>L.</given-names></name><name><surname>Madeo</surname><given-names>A.</given-names></name><name><surname>Lappano</surname><given-names>R.</given-names></name><name><surname>Vivacqua</surname><given-names>A.</given-names></name><name><surname>Rago</surname><given-names>V.</given-names></name><name><surname>Carpino</surname><given-names>A.</given-names></name><name><surname>Oprea</surname><given-names>T.I.</given-names></name><name><surname>Prossnitz</surname><given-names>E.R.</given-names></name><name><surname>Musti</surname><given-names>A.M.</given-names></name><name><surname>Ando</surname><given-names>S.</given-names></name><etal/></person-group><article-title>G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growthresponse to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancercells</article-title><source>Cancer Res.</source><year>2007</year><volume>67</volume><fpage>1859</fpage><lpage>1866</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-2909</pub-id><?supplied-pmid 17308128?><pub-id pub-id-type="pmid">17308128</pub-id></element-citation></ref><ref id="B44-cells-08-01123"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santolla</surname><given-names>M.F.</given-names></name><name><surname>Lappano</surname><given-names>R.</given-names></name><name><surname>De Marco</surname><given-names>P.</given-names></name><name><surname>Pupo</surname><given-names>M.</given-names></name><name><surname>Vivacqua</surname><given-names>A.</given-names></name><name><surname>Sisci</surname><given-names>D.</given-names></name><name><surname>Abonante</surname><given-names>S.</given-names></name><name><surname>Iacopetta</surname><given-names>D.</given-names></name><name><surname>Cappello</surname><given-names>A.R.</given-names></name><name><surname>Dolce</surname><given-names>V.</given-names></name><etal/></person-group><article-title>G protein-coupled estrogen receptor mediates the up-regulation of fatty acidsynthase induced by 17beta-estradiol in cancer cells and cancer-associatedfibroblasts</article-title><source>J. Biol. Chem.</source><year>2012</year><volume>287</volume><fpage>43234</fpage><lpage>43245</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.417303</pub-id><?supplied-pmid 23135268?><pub-id pub-id-type="pmid">23135268</pub-id></element-citation></ref><ref id="B45-cells-08-01123"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Francesco</surname><given-names>E.M.</given-names></name><name><surname>Pellegrino</surname><given-names>M.</given-names></name><name><surname>Santolla</surname><given-names>M.F.</given-names></name><name><surname>Lappano</surname><given-names>R.</given-names></name><name><surname>Ricchio</surname><given-names>E.</given-names></name><name><surname>Abonante</surname><given-names>S.</given-names></name><name><surname>Maggiolini</surname><given-names>M.</given-names></name></person-group><article-title>GPER mediates activation of HIF1alpha/VEGF signaling by estrogens</article-title><source>Cancer Res.</source><year>2014</year><volume>74</volume><fpage>4053</fpage><lpage>4064</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-3590</pub-id><?supplied-pmid 24894716?><pub-id pub-id-type="pmid">24894716</pub-id></element-citation></ref><ref id="B46-cells-08-01123"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hewitt</surname><given-names>S.C.</given-names></name><name><surname>Winuthayanon</surname><given-names>W.</given-names></name><name><surname>Korach</surname><given-names>K.S.</given-names></name></person-group><article-title>What&#x02019;s new in estrogen receptor action in the female reproductive tract</article-title><source>J. Mol. Endocrinol.</source><year>2016</year><volume>56</volume><fpage>R55</fpage><lpage>R71</lpage><pub-id pub-id-type="doi">10.1530/JME-15-0254</pub-id><?supplied-pmid 26826253?><pub-id pub-id-type="pmid">26826253</pub-id></element-citation></ref><ref id="B47-cells-08-01123"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>S.</given-names></name><name><surname>Rainville</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Katzenellenbogen</surname><given-names>B.S.</given-names></name><name><surname>Pfaff</surname><given-names>D.</given-names></name><name><surname>Vasudevan</surname><given-names>N.</given-names></name></person-group><article-title>Estrogen receptor-mediated transcription involves the activation of multiple kinase pathways in neuroblastoma cells</article-title><source>J. Steroid Biochem. Mol. Biol.</source><year>2014</year><volume>139</volume><fpage>45</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/j.jsbmb.2013.09.010</pub-id><pub-id pub-id-type="pmid">24121066</pub-id></element-citation></ref><ref id="B48-cells-08-01123"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalyanaraman</surname><given-names>H.</given-names></name><name><surname>Schwappacher</surname><given-names>R.</given-names></name><name><surname>Joshua</surname><given-names>J.</given-names></name><name><surname>Zhuang</surname><given-names>S.</given-names></name><name><surname>Scott</surname><given-names>B.T.</given-names></name><name><surname>Klos</surname><given-names>M.</given-names></name><name><surname>Casteel</surname><given-names>D.E.</given-names></name><name><surname>Frangos</surname><given-names>J.A.</given-names></name><name><surname>Dillmann</surname><given-names>W.</given-names></name><name><surname>Boss</surname><given-names>G.R.</given-names></name><etal/></person-group><article-title>Nongenomic thyroid hormone signaling occurs through a plasma membrane-localizedreceptor</article-title><source>Sci. Signal</source><year>2014</year><volume>7</volume><fpage>a48</fpage><pub-id pub-id-type="doi">10.1126/scisignal.2004911</pub-id></element-citation></ref><ref id="B49-cells-08-01123"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Razandi</surname><given-names>M.</given-names></name><name><surname>Oh</surname><given-names>P.</given-names></name><name><surname>Pedram</surname><given-names>A.</given-names></name><name><surname>Schnitzer</surname><given-names>J.</given-names></name><name><surname>Levin</surname><given-names>E.R.</given-names></name></person-group><article-title>ERs associate with and regulate the production of caveolin: Implications forsignaling and cellular actions</article-title><source>Mol. Endocrinol.</source><year>2002</year><volume>16</volume><fpage>100</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1210/mend.16.1.0757</pub-id><pub-id pub-id-type="pmid">11773442</pub-id></element-citation></ref><ref id="B50-cells-08-01123"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Razandi</surname><given-names>M.</given-names></name><name><surname>Pedram</surname><given-names>A.</given-names></name><name><surname>Greene</surname><given-names>G.L.</given-names></name><name><surname>Levin</surname><given-names>E.R.</given-names></name></person-group><article-title>Cell membrane and nuclear estrogen receptors (ERs) originate from a singletranscript: Studies of ERalpha and ERbeta expressed in Chinese hamster ovarycells</article-title><source>Mol. Endocrinol.</source><year>1999</year><volume>13</volume><fpage>307</fpage><lpage>319</lpage><pub-id pub-id-type="pmid">9973260</pub-id></element-citation></ref><ref id="B51-cells-08-01123"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>P.</given-names></name><name><surname>Wu</surname><given-names>Q.</given-names></name><name><surname>Chambliss</surname><given-names>K.L.</given-names></name><name><surname>Yuhanna</surname><given-names>I.S.</given-names></name><name><surname>Mumby</surname><given-names>S.M.</given-names></name><name><surname>Mineo</surname><given-names>C.</given-names></name><name><surname>Tall</surname><given-names>G.G.</given-names></name><name><surname>Shaul</surname><given-names>P.W.</given-names></name></person-group><article-title>Direct interactions with G alpha i and G betagamma mediate nongenomic signalingby estrogen receptor alpha</article-title><source>Mol. Endocrinol.</source><year>2007</year><volume>21</volume><fpage>1370</fpage><lpage>1380</lpage><pub-id pub-id-type="doi">10.1210/me.2006-0360</pub-id><?supplied-pmid 17405905?><pub-id pub-id-type="pmid">17405905</pub-id></element-citation></ref><ref id="B52-cells-08-01123"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>E.V.</given-names></name><name><surname>DeSombre</surname><given-names>E.R.</given-names></name></person-group><article-title>Estrogen-receptor interaction</article-title><source>Science</source><year>1973</year><volume>182</volume><fpage>126</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1126/science.182.4108.126</pub-id><?supplied-pmid 4354173?><pub-id pub-id-type="pmid">4354173</pub-id></element-citation></ref><ref id="B53-cells-08-01123"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>K.A.</given-names></name><name><surname>Carroll</surname><given-names>J.S.</given-names></name></person-group><article-title>Oestrogen-receptor-mediated transcription and the influence of co-factors and chromatin state</article-title><source>Nat. Rev. Cancer</source><year>2007</year><volume>7</volume><fpage>713</fpage><lpage>722</lpage><pub-id pub-id-type="doi">10.1038/nrc2211</pub-id><?supplied-pmid 17721435?><pub-id pub-id-type="pmid">17721435</pub-id></element-citation></ref><ref id="B54-cells-08-01123"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carroll</surname><given-names>J.S.</given-names></name><name><surname>Liu</surname><given-names>X.S.</given-names></name><name><surname>Brodsky</surname><given-names>A.S.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Meyer</surname><given-names>C.A.</given-names></name><name><surname>Szary</surname><given-names>A.J.</given-names></name><name><surname>Eeckhoute</surname><given-names>J.</given-names></name><name><surname>Shao</surname><given-names>W.</given-names></name><name><surname>Hestermann</surname><given-names>E.V.</given-names></name><name><surname>Geistlinger</surname><given-names>T.R.</given-names></name><etal/></person-group><article-title>Chromosome-wide mapping of estrogen receptor binding reveals long-rangeregulation requiring the forkhead protein FoxA1</article-title><source>Cell</source><year>2005</year><volume>122</volume><fpage>33</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2005.05.008</pub-id><?supplied-pmid 16009131?><pub-id pub-id-type="pmid">16009131</pub-id></element-citation></ref><ref id="B55-cells-08-01123"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hewitt</surname><given-names>S.C.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Grimm</surname><given-names>S.A.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Bushel</surname><given-names>P.R.</given-names></name><name><surname>Fargo</surname><given-names>D.</given-names></name><name><surname>Korach</surname><given-names>K.S.</given-names></name></person-group><article-title>Research resource: Whole-genome estrogen receptor alpha binding in mouse uterine tissue revealed by ChIP-seq</article-title><source>Mol. Endocrinol.</source><year>2012</year><volume>26</volume><fpage>887</fpage><lpage>898</lpage><pub-id pub-id-type="doi">10.1210/me.2011-1311</pub-id><pub-id pub-id-type="pmid">22446102</pub-id></element-citation></ref><ref id="B56-cells-08-01123"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carroll</surname><given-names>J.S.</given-names></name><name><surname>Brown</surname><given-names>M.</given-names></name></person-group><article-title>Estrogen receptor target gene: An evolving concept</article-title><source>Mol. Endocrinol.</source><year>2006</year><volume>20</volume><fpage>1707</fpage><lpage>1714</lpage><pub-id pub-id-type="doi">10.1210/me.2005-0334</pub-id><?supplied-pmid 16396959?><pub-id pub-id-type="pmid">16396959</pub-id></element-citation></ref><ref id="B57-cells-08-01123"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jakacka</surname><given-names>M.</given-names></name><name><surname>Ito</surname><given-names>M.</given-names></name><name><surname>Weiss</surname><given-names>J.</given-names></name><name><surname>Chien</surname><given-names>P.Y.</given-names></name><name><surname>Gehm</surname><given-names>B.D.</given-names></name><name><surname>Jameson</surname><given-names>J.L.</given-names></name></person-group><article-title>Estrogen receptor binding to DNA is not required for its activity through thenonclassical AP1 pathway</article-title><source>J. Biol. Chem.</source><year>2001</year><volume>276</volume><fpage>13615</fpage><lpage>13621</lpage><pub-id pub-id-type="doi">10.1074/jbc.M008384200</pub-id><pub-id pub-id-type="pmid">11278408</pub-id></element-citation></ref><ref id="B58-cells-08-01123"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>C.L.</given-names></name></person-group><article-title>Cross-talk between peptide growth factor and estrogen receptor signalingpathways</article-title><source>Biol. Reprod.</source><year>1998</year><volume>58</volume><fpage>627</fpage><lpage>632</lpage><pub-id pub-id-type="doi">10.1095/biolreprod58.3.627</pub-id><pub-id pub-id-type="pmid">9510949</pub-id></element-citation></ref><ref id="B59-cells-08-01123"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maselli</surname><given-names>A.</given-names></name><name><surname>Pierdominici</surname><given-names>M.</given-names></name><name><surname>Vitale</surname><given-names>C.</given-names></name><name><surname>Ortona</surname><given-names>E.</given-names></name></person-group><article-title>Membrane lipid rafts and estrogenic signalling: A functional role in themodulation of cell homeostasis</article-title><source>Apoptosis</source><year>2015</year><volume>20</volume><fpage>671</fpage><lpage>678</lpage><pub-id pub-id-type="doi">10.1007/s10495-015-1093-5</pub-id><pub-id pub-id-type="pmid">25637184</pub-id></element-citation></ref><ref id="B60-cells-08-01123"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Wen</surname><given-names>Z.</given-names></name><name><surname>Kong</surname><given-names>F.</given-names></name><name><surname>Guan</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name></person-group><article-title>microRNA-206 overexpression inhibits cellular proliferation and invasion ofestrogen receptor alpha-positive ovarian cancer cells</article-title><source>Mol. Med. Rep.</source><year>2014</year><volume>9</volume><fpage>1703</fpage><lpage>1708</lpage><pub-id pub-id-type="doi">10.3892/mmr.2014.2021</pub-id><pub-id pub-id-type="pmid">24604205</pub-id></element-citation></ref><ref id="B61-cells-08-01123"><label>61.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>B.</given-names></name></person-group><article-title>Elucidating microRNA-Mediated Regulation of Estrogen Signaling and Response in Human Breast Cancer Cells</article-title><source>Ph.D.Thesis</source><publisher-name>University of Connecticut</publisher-name><publisher-loc>Mansfield, CT, USA</publisher-loc><day>1</day><month>1</month><year>2009</year></element-citation></ref><ref id="B62-cells-08-01123"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>J.</given-names></name><name><surname>Ye</surname><given-names>L.</given-names></name><name><surname>Ding</surname><given-names>J.</given-names></name><name><surname>Feng</surname><given-names>W.</given-names></name><name><surname>Jin</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Hua</surname><given-names>K.</given-names></name></person-group><article-title>Expression and clinical significance of estrogen-regulated long non-coding RNAsin estrogen receptor alpha-positive ovarian cancer progression</article-title><source>Oncol. Rep.</source><year>2014</year><volume>31</volume><fpage>1613</fpage><lpage>1622</lpage><pub-id pub-id-type="doi">10.3892/or.2014.3000</pub-id><?supplied-pmid 24481591?><pub-id pub-id-type="pmid">24481591</pub-id></element-citation></ref><ref id="B63-cells-08-01123"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bossard</surname><given-names>C.</given-names></name><name><surname>Busson</surname><given-names>M.</given-names></name><name><surname>Vindrieux</surname><given-names>D.</given-names></name><name><surname>Gaudin</surname><given-names>F.</given-names></name><name><surname>Machelon</surname><given-names>V.</given-names></name><name><surname>Brigitte</surname><given-names>M.</given-names></name><name><surname>Jacquard</surname><given-names>C.</given-names></name><name><surname>Pillon</surname><given-names>A.</given-names></name><name><surname>Balaguer</surname><given-names>P.</given-names></name><name><surname>Balabanian</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Potential role of estrogen receptor beta as a tumor suppressor of epithelialovarian cancer</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e44787</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0044787</pub-id><?supplied-pmid 22970307?><pub-id pub-id-type="pmid">22970307</pub-id></element-citation></ref><ref id="B64-cells-08-01123"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Stefano</surname><given-names>I.</given-names></name><name><surname>Zannoni</surname><given-names>G.F.</given-names></name><name><surname>Prisco</surname><given-names>M.G.</given-names></name><name><surname>Fagotti</surname><given-names>A.</given-names></name><name><surname>Tortorella</surname><given-names>L.</given-names></name><name><surname>Vizzielli</surname><given-names>G.</given-names></name><name><surname>Mencaglia</surname><given-names>L.</given-names></name><name><surname>Scambia</surname><given-names>G.</given-names></name><name><surname>Gallo</surname><given-names>D.</given-names></name></person-group><article-title>Cytoplasmic expression of estrogen receptor beta (ERbeta) predicts poor clinical outcome in advanced serous ovarian cancer</article-title><source>Gynecol. Oncol.</source><year>2011</year><volume>122</volume><fpage>573</fpage><lpage>579</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2011.05.025</pub-id><?supplied-pmid 21665249?><pub-id pub-id-type="pmid">21665249</pub-id></element-citation></ref><ref id="B65-cells-08-01123"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciucci</surname><given-names>A.</given-names></name><name><surname>Zannoni</surname><given-names>G.F.</given-names></name><name><surname>Travaglia</surname><given-names>D.</given-names></name><name><surname>Petrillo</surname><given-names>M.</given-names></name><name><surname>Scambia</surname><given-names>G.</given-names></name><name><surname>Gallo</surname><given-names>D.</given-names></name></person-group><article-title>Prognostic significance of the estrogen receptor beta (ERbeta) isoforms ERbeta1, ERbeta2, and ERbeta5 in advanced serous ovarian cancer</article-title><source>Gynecol. Oncol.</source><year>2014</year><volume>132</volume><fpage>351</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2013.12.027</pub-id><?supplied-pmid 24378878?><pub-id pub-id-type="pmid">24378878</pub-id></element-citation></ref><ref id="B66-cells-08-01123"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Viswanadhapalli</surname><given-names>S.</given-names></name><name><surname>Garcia</surname><given-names>L.</given-names></name><name><surname>Zhou</surname><given-names>M.</given-names></name><name><surname>Nair</surname><given-names>B.C.</given-names></name><name><surname>Kost</surname><given-names>E.</given-names></name><name><surname>Rao Tekmal</surname><given-names>R.</given-names></name><name><surname>Li</surname><given-names>R.</given-names></name><name><surname>Rao</surname><given-names>M.K.</given-names></name><name><surname>Curiel</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Therapeutic utility of natural estrogen receptor beta agonists on ovarian cancer</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>50002</fpage><lpage>50014</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.18442</pub-id><?supplied-pmid 28654894?><pub-id pub-id-type="pmid">28654894</pub-id></element-citation></ref><ref id="B67-cells-08-01123"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giudice</surname><given-names>L.C.</given-names></name></person-group><article-title>Clinical practice. Endometriosis</article-title><source>N. Engl. J. Med.</source><year>2010</year><volume>362</volume><fpage>2389</fpage><lpage>2398</lpage><pub-id pub-id-type="doi">10.1056/NEJMcp1000274</pub-id><?supplied-pmid 20573927?><pub-id pub-id-type="pmid">20573927</pub-id></element-citation></ref><ref id="B68-cells-08-01123"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozkan</surname><given-names>S.</given-names></name><name><surname>Murk</surname><given-names>W.</given-names></name><name><surname>Arici</surname><given-names>A.</given-names></name></person-group><article-title>Endometriosis and infertility: Epidemiology and evidence-based treatments</article-title><source>Ann. Ny. Acad. Sci.</source><year>2008</year><volume>1127</volume><fpage>92</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1196/annals.1434.007</pub-id><?supplied-pmid 18443335?><pub-id pub-id-type="pmid">18443335</pub-id></element-citation></ref><ref id="B69-cells-08-01123"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Yu</surname><given-names>Q.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Yan</surname><given-names>L.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name></person-group><article-title>The estrogen-regulated lncRNA H19/miR-216a-5p axis alters stromal cell invasionand migration via ACTA2 in endometriosis</article-title><source>Mol. Hum. Reprod.</source><year>2019</year><pub-id pub-id-type="doi">10.1093/molehr/gaz040</pub-id></element-citation></ref><ref id="B70-cells-08-01123"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delvoux</surname><given-names>B.</given-names></name><name><surname>Groothuis</surname><given-names>P.</given-names></name><name><surname>D&#x02019;Hooghe</surname><given-names>T.</given-names></name><name><surname>Kyama</surname><given-names>C.</given-names></name><name><surname>Dunselman</surname><given-names>G.</given-names></name><name><surname>Romano</surname><given-names>A.</given-names></name></person-group><article-title>Increased production of 17beta-estradiol in endometriosis lesions is the resultof impaired metabolism</article-title><source>J. Clin. Endocrinol. Metab.</source><year>2009</year><volume>94</volume><fpage>876</fpage><lpage>883</lpage><pub-id pub-id-type="doi">10.1210/jc.2008-2218</pub-id><pub-id pub-id-type="pmid">19088158</pub-id></element-citation></ref><ref id="B71-cells-08-01123"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hewitt</surname><given-names>S.C.</given-names></name><name><surname>Korach</surname><given-names>K.S.</given-names></name></person-group><article-title>Oestrogen receptor knockout mice: Roles for oestrogen receptors alpha and beta inreproductive tissues</article-title><source>Reproduction</source><year>2003</year><volume>125</volume><fpage>143</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1530/rep.0.1250143</pub-id><pub-id pub-id-type="pmid">12578528</pub-id></element-citation></ref><ref id="B72-cells-08-01123"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Gong</surname><given-names>P.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Nwachukwu</surname><given-names>J.C.</given-names></name><name><surname>Srinivasan</surname><given-names>S.</given-names></name><name><surname>Ko</surname><given-names>C.</given-names></name><name><surname>Bagchi</surname><given-names>M.K.</given-names></name><name><surname>Taylor</surname><given-names>R.N.</given-names></name><name><surname>Korach</surname><given-names>K.S.</given-names></name><name><surname>Nettles</surname><given-names>K.W.</given-names></name><etal/></person-group><article-title>Dual suppression of estrogenic and inflammatory activities for targeting of endometriosis</article-title><source>Sci. Transl. Med.</source><year>2015</year><volume>7</volume><fpage>271r</fpage><lpage>279r</lpage><pub-id pub-id-type="doi">10.1126/scitranslmed.3010626</pub-id><?supplied-pmid 25609169?><pub-id pub-id-type="pmid">25609169</pub-id></element-citation></ref><ref id="B73-cells-08-01123"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burney</surname><given-names>R.O.</given-names></name></person-group><article-title>The genetics and biochemistry of endometriosis</article-title><source>Curr. Opin. Obstet. Gyn.</source><year>2013</year><volume>25</volume><fpage>280</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1097/GCO.0b013e3283630d56</pub-id><?supplied-pmid 23759832?><pub-id pub-id-type="pmid">23759832</pub-id></element-citation></ref><ref id="B74-cells-08-01123"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burns</surname><given-names>K.A.</given-names></name><name><surname>Rodriguez</surname><given-names>K.F.</given-names></name><name><surname>Hewitt</surname><given-names>S.C.</given-names></name><name><surname>Janardhan</surname><given-names>K.S.</given-names></name><name><surname>Young</surname><given-names>S.L.</given-names></name><name><surname>Korach</surname><given-names>K.S.</given-names></name></person-group><article-title>Role of estrogen receptor signaling required for endometriosis-like lesion establishment in a mouse model</article-title><source>Endocrinology</source><year>2012</year><volume>153</volume><fpage>3960</fpage><lpage>3971</lpage><pub-id pub-id-type="doi">10.1210/en.2012-1294</pub-id><?supplied-pmid 22700766?><pub-id pub-id-type="pmid">22700766</pub-id></element-citation></ref><ref id="B75-cells-08-01123"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>S.J.</given-names></name><name><surname>O&#x02019;Malley</surname><given-names>B.W.</given-names></name></person-group><article-title>The dynamics of nuclear receptors and nuclear receptor coregulators in the pathogenesis of endometriosis</article-title><source>Hum. Reprod. Update</source><year>2014</year><volume>20</volume><fpage>467</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.1093/humupd/dmu002</pub-id><?supplied-pmid 24634322?><pub-id pub-id-type="pmid">24634322</pub-id></element-citation></ref><ref id="B76-cells-08-01123"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>S.J.</given-names></name><name><surname>Jung</surname><given-names>S.Y.</given-names></name><name><surname>Wu</surname><given-names>S.</given-names></name><name><surname>Hawkins</surname><given-names>S.M.</given-names></name><name><surname>Park</surname><given-names>M.J.</given-names></name><name><surname>Kyo</surname><given-names>S.</given-names></name><name><surname>Qin</surname><given-names>J.</given-names></name><name><surname>Lydon</surname><given-names>J.P.</given-names></name><name><surname>Tsai</surname><given-names>S.Y.</given-names></name><name><surname>Tsai</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Estrogen Receptor beta Modulates Apoptosis Complexes and the Inflammasome toDrive the Pathogenesis of Endometriosis</article-title><source>Cell</source><year>2015</year><volume>163</volume><fpage>960</fpage><lpage>974</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.10.034</pub-id><pub-id pub-id-type="pmid">26544941</pub-id></element-citation></ref><ref id="B77-cells-08-01123"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monsivais</surname><given-names>D.</given-names></name><name><surname>Dyson</surname><given-names>M.T.</given-names></name><name><surname>Yin</surname><given-names>P.</given-names></name><name><surname>Navarro</surname><given-names>A.</given-names></name><name><surname>Coon</surname><given-names>J.S.T.</given-names></name><name><surname>Pavone</surname><given-names>M.E.</given-names></name><name><surname>Bulun</surname><given-names>S.E.</given-names></name></person-group><article-title>Estrogen receptor beta regulates endometriotic cell survival through serum andglucocorticoid-regulated kinase activation</article-title><source>Fertil. Steril.</source><year>2016</year><volume>105</volume><fpage>1266</fpage><lpage>1273</lpage><pub-id pub-id-type="doi">10.1016/j.fertnstert.2016.01.012</pub-id><pub-id pub-id-type="pmid">26827666</pub-id></element-citation></ref><ref id="B78-cells-08-01123"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monsivais</surname><given-names>D.</given-names></name><name><surname>Dyson</surname><given-names>M.T.</given-names></name><name><surname>Yin</surname><given-names>P.</given-names></name><name><surname>Coon</surname><given-names>J.S.</given-names></name><name><surname>Navarro</surname><given-names>A.</given-names></name><name><surname>Feng</surname><given-names>G.</given-names></name><name><surname>Malpani</surname><given-names>S.S.</given-names></name><name><surname>Ono</surname><given-names>M.</given-names></name><name><surname>Ercan</surname><given-names>C.M.</given-names></name><name><surname>Wei</surname><given-names>J.J.</given-names></name><etal/></person-group><article-title>ERbeta- and prostaglandin E2-regulated pathways integrate cell proliferation via Ras-like and estrogen-regulated growth inhibitor in endometriosis</article-title><source>Mol. Endocrinol.</source><year>2014</year><volume>28</volume><fpage>1304</fpage><lpage>1315</lpage><pub-id pub-id-type="doi">10.1210/me.2013-1421</pub-id><pub-id pub-id-type="pmid">24992181</pub-id></element-citation></ref><ref id="B79-cells-08-01123"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bulun</surname><given-names>S.E.</given-names></name><name><surname>Yilmaz</surname><given-names>B.D.</given-names></name><name><surname>Sison</surname><given-names>C.</given-names></name><name><surname>Miyazaki</surname><given-names>K.</given-names></name><name><surname>Bernardi</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Kohlmeier</surname><given-names>A.</given-names></name><name><surname>Yin</surname><given-names>P.</given-names></name><name><surname>Milad</surname><given-names>M.</given-names></name><name><surname>Wei</surname><given-names>J.</given-names></name></person-group><article-title>Endometriosis</article-title><source>Endocr. Rev.</source><year>2019</year><volume>40</volume><fpage>1048</fpage><lpage>1079</lpage><pub-id pub-id-type="doi">10.1210/er.2018-00242</pub-id><pub-id pub-id-type="pmid">30994890</pub-id></element-citation></ref><ref id="B80-cells-08-01123"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heublein</surname><given-names>S.</given-names></name><name><surname>Lenhard</surname><given-names>M.</given-names></name><name><surname>Vrekoussis</surname><given-names>T.</given-names></name><name><surname>Schoepfer</surname><given-names>J.</given-names></name><name><surname>Kuhn</surname><given-names>C.</given-names></name><name><surname>Friese</surname><given-names>K.</given-names></name><name><surname>Makrigiannakis</surname><given-names>A.</given-names></name><name><surname>Mayr</surname><given-names>D.</given-names></name><name><surname>Jeschke</surname><given-names>U.</given-names></name></person-group><article-title>The G-protein-coupled estrogen receptor (GPER) is expressed in normal humanovaries and is upregulated in ovarian endometriosis and pelvic inflammatorydisease involving the ovary</article-title><source>Reprod. Sci.</source><year>2012</year><volume>19</volume><fpage>1197</fpage><lpage>1204</lpage><pub-id pub-id-type="doi">10.1177/1933719112446085</pub-id><pub-id pub-id-type="pmid">22573494</pub-id></element-citation></ref><ref id="B81-cells-08-01123"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plante</surname><given-names>B.J.</given-names></name><name><surname>Lessey</surname><given-names>B.A.</given-names></name><name><surname>Taylor</surname><given-names>R.N.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Bagchi</surname><given-names>M.K.</given-names></name><name><surname>Yuan</surname><given-names>L.</given-names></name><name><surname>Scotchie</surname><given-names>J.</given-names></name><name><surname>Fritz</surname><given-names>M.A.</given-names></name><name><surname>Young</surname><given-names>S.L.</given-names></name></person-group><article-title>G protein-coupled estrogen receptor (GPER) expression in normal and abnormalendometrium</article-title><source>Reprod. Sci.</source><year>2012</year><volume>19</volume><fpage>684</fpage><lpage>693</lpage><pub-id pub-id-type="doi">10.1177/1933719111431000</pub-id><pub-id pub-id-type="pmid">22378861</pub-id></element-citation></ref><ref id="B82-cells-08-01123"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koppitz</surname><given-names>M.</given-names></name><name><surname>Brauer</surname><given-names>N.</given-names></name><name><surname>Ter Laak</surname><given-names>A.</given-names></name><name><surname>Irlbacher</surname><given-names>H.</given-names></name><name><surname>Rotgeri</surname><given-names>A.</given-names></name><name><surname>Coelho</surname><given-names>A.</given-names></name><name><surname>Walter</surname><given-names>D.</given-names></name><name><surname>Steinmeyer</surname><given-names>A.</given-names></name><name><surname>Zollner</surname><given-names>T.M.</given-names></name><name><surname>Peters</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Discovery and optimization of pyridyl-cycloalkyl-carboxylic acids as inhibitorsof microsomal prostaglandin E synthase-1 for the treatment of endometriosis</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2019</year><pub-id pub-id-type="doi">10.1016/j.bmcl.2019.07.007</pub-id></element-citation></ref><ref id="B83-cells-08-01123"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farrell</surname><given-names>K.</given-names></name><name><surname>Antoni</surname><given-names>M.H.</given-names></name></person-group><article-title>Insulin resistance, obesity, inflammation, and depression in polycystic ovary syndrome: Biobehavioral mechanisms and interventions</article-title><source>Fertil. Steril.</source><year>2010</year><volume>94</volume><fpage>1565</fpage><lpage>1574</lpage><pub-id pub-id-type="doi">10.1016/j.fertnstert.2010.03.081</pub-id><pub-id pub-id-type="pmid">20471009</pub-id></element-citation></ref><ref id="B84-cells-08-01123"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azziz</surname><given-names>R.</given-names></name><name><surname>Carmina</surname><given-names>E.</given-names></name><name><surname>Dewailly</surname><given-names>D.</given-names></name><name><surname>Diamanti-Kandarakis</surname><given-names>E.</given-names></name><name><surname>Escobar-Morreale</surname><given-names>H.F.</given-names></name><name><surname>Futterweit</surname><given-names>W.</given-names></name><name><surname>Janssen</surname><given-names>O.E.</given-names></name><name><surname>Legro</surname><given-names>R.S.</given-names></name><name><surname>Norman</surname><given-names>R.J.</given-names></name><name><surname>Taylor</surname><given-names>A.E.</given-names></name><etal/></person-group><article-title>Positions statement: Criteria for defining polycystic ovary syndrome as apredominantly hyperandrogenic syndrome: An Androgen Excess Society guideline</article-title><source>J. Clin. Endocrinol. Metab.</source><year>2006</year><volume>91</volume><fpage>4237</fpage><lpage>4245</lpage><pub-id pub-id-type="doi">10.1210/jc.2006-0178</pub-id><pub-id pub-id-type="pmid">16940456</pub-id></element-citation></ref><ref id="B85-cells-08-01123"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hiam</surname><given-names>D.</given-names></name><name><surname>Simar</surname><given-names>D.</given-names></name><name><surname>Laker</surname><given-names>R.</given-names></name><name><surname>Altintas</surname><given-names>A.</given-names></name><name><surname>Gibson-Helm</surname><given-names>M.</given-names></name><name><surname>Fletcher</surname><given-names>E.</given-names></name><name><surname>Moreno-Asso</surname><given-names>A.</given-names></name><name><surname>Trewin</surname><given-names>A.J.</given-names></name><name><surname>Barres</surname><given-names>R.</given-names></name><name><surname>Stepto</surname><given-names>N.K.</given-names></name></person-group><article-title>Epigenetic reprogramming of immune cells in women with PCOS impact genescontrolling reproductive function</article-title><source>J. Clin. Endocrinol. Metab.</source><year>2019</year><pub-id pub-id-type="doi">10.1210/jc.2019-01015</pub-id></element-citation></ref><ref id="B86-cells-08-01123"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cobin</surname><given-names>R.H.</given-names></name></person-group><article-title>Cardiovascular and metabolic risks associated with PCOS</article-title><source>Intern. Emerg. Med.</source><year>2013</year><volume>8</volume><fpage>61</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1007/s11739-013-0924-z</pub-id></element-citation></ref><ref id="B87-cells-08-01123"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hart</surname><given-names>R.</given-names></name><name><surname>Doherty</surname><given-names>D.A.</given-names></name></person-group><article-title>The potential implications of a PCOS diagnosis on a woman&#x02019;s long-term healthusing data linkage</article-title><source>J. Clin. Endocrinol. Metab.</source><year>2015</year><volume>100</volume><fpage>911</fpage><lpage>919</lpage><pub-id pub-id-type="doi">10.1210/jc.2014-3886</pub-id><pub-id pub-id-type="pmid">25532045</pub-id></element-citation></ref><ref id="B88-cells-08-01123"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barry</surname><given-names>J.A.</given-names></name><name><surname>Azizia</surname><given-names>M.M.</given-names></name><name><surname>Hardiman</surname><given-names>P.J.</given-names></name></person-group><article-title>Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: A systematic review and meta-analysis</article-title><source>Hum. Reprod. Update</source><year>2014</year><volume>20</volume><fpage>748</fpage><lpage>758</lpage><pub-id pub-id-type="doi">10.1093/humupd/dmu012</pub-id><pub-id pub-id-type="pmid">24688118</pub-id></element-citation></ref><ref id="B89-cells-08-01123"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia</surname><given-names>E.</given-names></name><name><surname>Bouchard</surname><given-names>P.</given-names></name><name><surname>De Brux</surname><given-names>J.</given-names></name><name><surname>Berdah</surname><given-names>J.</given-names></name><name><surname>Frydman</surname><given-names>R.</given-names></name><name><surname>Schaison</surname><given-names>G.</given-names></name><name><surname>Milgrom</surname><given-names>E.</given-names></name><name><surname>Perrot-Applanat</surname><given-names>M.</given-names></name></person-group><article-title>Use of immunocytochemistry of progesterone and estrogen receptors for endometrialdating</article-title><source>J. Clin. Endocrinol. Metab.</source><year>1998</year><volume>67</volume><fpage>80</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1210/jcem-67-1-80</pub-id></element-citation></ref><ref id="B90-cells-08-01123"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lecce</surname><given-names>G.</given-names></name><name><surname>Meduri</surname><given-names>G.</given-names></name><name><surname>Ancelin</surname><given-names>M.</given-names></name><name><surname>Bergeron</surname><given-names>C.</given-names></name><name><surname>Perrot-Applanat</surname><given-names>M.</given-names></name></person-group><article-title>Presence of estrogen receptor beta in the human endometrium through the cycle: Expression in glandular, stromal, and vascular cells</article-title><source>J. Clin. Endocrinol. Metab.</source><year>2001</year><volume>86</volume><fpage>1379</fpage><lpage>1386</lpage><pub-id pub-id-type="pmid">11238535</pub-id></element-citation></ref><ref id="B91-cells-08-01123"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehasseb</surname><given-names>M.K.</given-names></name><name><surname>Panchal</surname><given-names>R.</given-names></name><name><surname>Taylor</surname><given-names>A.H.</given-names></name><name><surname>Brown</surname><given-names>L.</given-names></name><name><surname>Bell</surname><given-names>S.C.</given-names></name><name><surname>Habiba</surname><given-names>M.</given-names></name></person-group><article-title>Estrogen and progesterone receptor isoform distribution through the menstrualcycle in uteri with and without adenomyosis</article-title><source>Fertil. Steril.</source><year>2011</year><volume>95</volume><fpage>2228</fpage><lpage>2235</lpage><pub-id pub-id-type="doi">10.1016/j.fertnstert.2011.02.051</pub-id><pub-id pub-id-type="pmid">21444077</pub-id></element-citation></ref><ref id="B92-cells-08-01123"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gregory</surname><given-names>C.W.</given-names></name><name><surname>Wilson</surname><given-names>E.M.</given-names></name><name><surname>Apparao</surname><given-names>K.B.C.</given-names></name><name><surname>Lininger</surname><given-names>R.A.</given-names></name><name><surname>Meyer</surname><given-names>W.R.</given-names></name><name><surname>Kowalik</surname><given-names>A.</given-names></name><name><surname>Fritz</surname><given-names>M.A.</given-names></name><name><surname>Lessey</surname><given-names>B.A.</given-names></name></person-group><article-title>Steroid receptor coactivator expression throughout the menstrual cycle in normal and abnormal endometrium</article-title><source>J. Clin. Endocrinol. Metab.</source><year>2006</year><volume>87</volume><fpage>2960</fpage><lpage>2966</lpage><pub-id pub-id-type="doi">10.1210/jcem.87.6.8572</pub-id></element-citation></ref><ref id="B93-cells-08-01123"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quezada</surname><given-names>S.</given-names></name><name><surname>Avellaira</surname><given-names>C.</given-names></name><name><surname>Johnson</surname><given-names>M.C.</given-names></name><name><surname>Gabler</surname><given-names>F.</given-names></name><name><surname>Fuentes</surname><given-names>A.</given-names></name><name><surname>Vega</surname><given-names>M.</given-names></name></person-group><article-title>Evaluation of steroid receptors, coregulators, and molecules associated withuterine receptivity in secretory endometria from untreated women with polycystic ovary syndrome</article-title><source>Fertil. Steril.</source><year>2006</year><volume>85</volume><fpage>1017</fpage><lpage>1026</lpage><pub-id pub-id-type="doi">10.1016/j.fertnstert.2005.09.053</pub-id><pub-id pub-id-type="pmid">16580389</pub-id></element-citation></ref><ref id="B94-cells-08-01123"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J.Y.</given-names></name><name><surname>Song</surname><given-names>H.</given-names></name><name><surname>Kim</surname><given-names>H.</given-names></name><name><surname>Kang</surname><given-names>H.J.</given-names></name><name><surname>Jun</surname><given-names>J.H.</given-names></name><name><surname>Hong</surname><given-names>S.R.</given-names></name><name><surname>Koong</surname><given-names>M.K.</given-names></name><name><surname>Kim</surname><given-names>I.S.</given-names></name></person-group><article-title>Transcriptional profiling with a pathway-oriented analysis identifiesdysregulated molecular phenotypes in the endometrium of patients with polycystic ovary syndrome</article-title><source>J. Clin. Endocrinol. Metab.</source><year>2009</year><volume>94</volume><fpage>1416</fpage><lpage>1426</lpage><pub-id pub-id-type="doi">10.1210/jc.2008-1612</pub-id><pub-id pub-id-type="pmid">19141577</pub-id></element-citation></ref><ref id="B95-cells-08-01123"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piltonen</surname><given-names>T.T.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Erikson</surname><given-names>D.W.</given-names></name><name><surname>Spitzer</surname><given-names>T.L.B.</given-names></name><name><surname>Barragan</surname><given-names>F.</given-names></name><name><surname>Rabban</surname><given-names>J.T.</given-names></name><name><surname>Huddleston</surname><given-names>H.</given-names></name><name><surname>Irwin</surname><given-names>J.C.</given-names></name><name><surname>Giudice</surname><given-names>L.C.</given-names></name></person-group><article-title>Mesenchymal stem/progenitors and other endometrial cell types from women withpolycystic ovary syndrome (PCOS) display inflammatory and oncogenic potential</article-title><source>J. Clin. Endocrinol. Metab.</source><year>2013</year><volume>98</volume><fpage>3765</fpage><lpage>3775</lpage><pub-id pub-id-type="doi">10.1210/jc.2013-1923</pub-id><pub-id pub-id-type="pmid">23824412</pub-id></element-citation></ref><ref id="B96-cells-08-01123"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rothenberg</surname><given-names>S.S.</given-names></name><name><surname>Beverley</surname><given-names>R.</given-names></name><name><surname>Barnard</surname><given-names>E.</given-names></name><name><surname>Baradaran-Shoraka</surname><given-names>M.</given-names></name><name><surname>Sanfilippo</surname><given-names>J.S.</given-names></name></person-group><article-title>Polycystic ovary syndrome in adolescents</article-title><source>Best Pract. Res. Clin. Haematol.</source><year>2018</year><volume>48</volume><fpage>103</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1016/j.bpobgyn.2017.08.008</pub-id></element-citation></ref><ref id="B97-cells-08-01123"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Witchel</surname><given-names>S.F.</given-names></name><name><surname>Oberfield</surname><given-names>S.E.</given-names></name><name><surname>Pena</surname><given-names>A.S.</given-names></name></person-group><article-title>Polycystic Ovary Syndrome: Pathophysiology, Presentation, and Treatment WithEmphasis on Adolescent Girls</article-title><source>J. Endocrine Soc.</source><year>2019</year><volume>3</volume><fpage>1545</fpage><lpage>1573</lpage><pub-id pub-id-type="doi">10.1210/js.2019-00078</pub-id><pub-id pub-id-type="pmid">31384717</pub-id></element-citation></ref><ref id="B98-cells-08-01123"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hosseini</surname><given-names>E.</given-names></name><name><surname>Shahhoseini</surname><given-names>M.</given-names></name><name><surname>Afsharian</surname><given-names>P.</given-names></name><name><surname>Karimian</surname><given-names>L.</given-names></name><name><surname>Ashrafi</surname><given-names>M.</given-names></name><name><surname>Mehraein</surname><given-names>F.</given-names></name><name><surname>Afatoonian</surname><given-names>R.</given-names></name></person-group><article-title>Role of epigenetic modifications in the aberrant CYP19A1 gene expression inpolycystic ovary syndrome</article-title><source>Arch. Med. Sci.</source><year>2019</year><volume>15</volume><fpage>887</fpage><lpage>895</lpage><pub-id pub-id-type="doi">10.5114/aoms.2019.86060</pub-id><pub-id pub-id-type="pmid">31360184</pub-id></element-citation></ref><ref id="B99-cells-08-01123"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuiper</surname><given-names>G.G.</given-names></name><name><surname>Carlsson</surname><given-names>B.</given-names></name><name><surname>Grandien</surname><given-names>K.</given-names></name><name><surname>Enmark</surname><given-names>E.</given-names></name><name><surname>Haggblad</surname><given-names>J.</given-names></name><name><surname>Nilsson</surname><given-names>S.</given-names></name><name><surname>Gustafsson</surname><given-names>J.A.</given-names></name></person-group><article-title>Comparison of the ligand binding specificity and transcript tissue distributionof estrogen receptors alpha and beta</article-title><source>Endocrinology</source><year>1997</year><volume>138</volume><fpage>863</fpage><lpage>870</lpage><pub-id pub-id-type="doi">10.1210/endo.138.3.4979</pub-id><pub-id pub-id-type="pmid">9048584</pub-id></element-citation></ref><ref id="B100-cells-08-01123"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ariazi</surname><given-names>E.A.</given-names></name><name><surname>Ariazi</surname><given-names>J.L.</given-names></name><name><surname>Cordera</surname><given-names>F.</given-names></name><name><surname>Jordan</surname><given-names>V.C.</given-names></name></person-group><article-title>Estrogen receptors as therapeutic targets in breast cancer</article-title><source>Curr. Top Med. Chem.</source><year>2006</year><volume>6</volume><fpage>181</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.2174/156802606776173483</pub-id><pub-id pub-id-type="pmid">16515478</pub-id></element-citation></ref><ref id="B101-cells-08-01123"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrie</surname><given-names>W.K.</given-names></name><name><surname>Dennis</surname><given-names>M.K.</given-names></name><name><surname>Hu</surname><given-names>C.</given-names></name><name><surname>Dai</surname><given-names>D.</given-names></name><name><surname>Arterburn</surname><given-names>J.B.</given-names></name><name><surname>Smith</surname><given-names>H.O.</given-names></name><name><surname>Hathaway</surname><given-names>H.J.</given-names></name><name><surname>Prossnitz</surname><given-names>E.R.</given-names></name></person-group><article-title>G protein-coupled estrogen receptor-selective ligands modulate endometrial tumor growth</article-title><source>Obst. Gynecol. Int.</source><year>2013</year><volume>2013</volume><fpage>472720</fpage><pub-id pub-id-type="doi">10.1155/2013/472720</pub-id><pub-id pub-id-type="pmid">24379833</pub-id></element-citation></ref><ref id="B102-cells-08-01123"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blair</surname><given-names>R.M.</given-names></name><name><surname>Fang</surname><given-names>H.</given-names></name><name><surname>Branham</surname><given-names>W.S.</given-names></name><name><surname>Hass</surname><given-names>B.S.</given-names></name><name><surname>Dial</surname><given-names>S.L.</given-names></name><name><surname>Moland</surname><given-names>C.L.</given-names></name><name><surname>Tong</surname><given-names>W.</given-names></name><name><surname>Shi</surname><given-names>L.</given-names></name><name><surname>Perkins</surname><given-names>R.</given-names></name><name><surname>Sheehan</surname><given-names>D.M.</given-names></name></person-group><article-title>The estrogen receptor relative binding affinities of 188 natural andxenochemicals: Structural diversity of ligands</article-title><source>Toxicol. Sci.</source><year>2000</year><volume>54</volume><fpage>138</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1093/toxsci/54.1.138</pub-id><?supplied-pmid 10746941?><pub-id pub-id-type="pmid">10746941</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="cells-08-01123-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>G-protein-coupled estrogen receptor (GPER) and agonists and antagonists of cell-membrane-bound receptors derived from estrogen receptor (ER)&#x003b1; and ER&#x003b2;, involved in rapid intracellular signal transduction. Arrows indicate activation, blocked arrows indicate inhibition, and dashed lines indicate tissue-specific activation or inhibition.</p></caption><graphic xlink:href="cells-08-01123-g001"/></fig><fig id="cells-08-01123-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Expression of ER&#x003b2; in endometriosis. ER&#x003b2; mainly participates in endometriosis through the following ways: Inhibiting TNF&#x003b1;-mediated apoptosis, inducing an increase in interleukin-1, and co-stimulating Ras-related and estrogen-regulated growth inhibitor (REGE) expression with prostaglandin E2 (PGE2) under the action of estradiol. In addition, serum and glucocorticoid-regulated kinases (SGK1) is a co-targeting target of PGE2 and estradiol. These pathways lead to proliferation of endometriosis cells.</p></caption><graphic xlink:href="cells-08-01123-g002"/></fig><fig id="cells-08-01123-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Structures of synthetic therapeutic drugs: (<bold>a</bold>) diethylstilbestrol; (<bold>b</bold>) 4-hydroxytamoxifen; (<bold>c</bold>) raloxifene; and (<bold>d</bold>) ethynylestradiol.</p></caption><graphic xlink:href="cells-08-01123-g003"/></fig></floats-group></article>